The Interplay between Pain/Stress, Inflammation and Microbiota in Human Health by Xu, Wanli
University of Connecticut
OpenCommons@UConn
Doctoral Dissertations University of Connecticut Graduate School
8-17-2018
The Interplay between Pain/Stress, Inflammation
and Microbiota in Human Health
Wanli Xu
University of Connecticut - Storrs, wanli.xu@uconn.edu
Follow this and additional works at: https://opencommons.uconn.edu/dissertations
Recommended Citation
Xu, Wanli, "The Interplay between Pain/Stress, Inflammation and Microbiota in Human Health" (2018). Doctoral Dissertations. 1949.
https://opencommons.uconn.edu/dissertations/1949
The Interplay between Pain/Stress, Inflammation and Microbiota in Human Health 
Wanli Xu, PhD 
University of Connecticut, 2018 
Pain/stress, microbiome, and immune responses have emerged as key elements regulating 
human’s health and disease. However, the mechanisms of their interplay with each other remain 
unclear. This manuscript style dissertation focused on the understanding of how pain/stress and 
microbiota influence the immune system and regulate the immune response. First, a nationwide 
online survey was conducted to develop an objective instrument to quantitatively measure 
cumulative pain/stress among NICU infants. Secondly, blood microbiome was investigated to 
examine the association between microbial translocation and plasma anti-CD4 autoantibodies in 
HIV+ subjects under long-term viral suppressive ART treatment. We found that plasma anti-
CD4 IgG level was associated with elevated microbial translocation, reduced microbial diversity 
and distinct microbial composition in HIV+ patients, suggesting that systemic microbial 
translocation and microbiome may associate with anti-CD4 autoantibody production in ART-
treated HIV disease. Lastly, a secondary data analysis was conducted to examine the relationship 
between cumulative pain/stress and Fecal calprotectin (FCP) level, a measurement of gut 
inflammatory responses, in preterm infants. We show that chronic (prolonged) pain/stress 
derived from daily medical procedures in the neonatal intensive care unit is positively associated 
with FCP levels. The study provides, to the best of our knowledge, the first insight of the 
modulation of prolonged pain/stress in the early programming of the gut immune system in 
preterm infants.	These results suggest pain/stress and microbiome are essential factors in 
regulating immune responses. Understanding the mechanism will help with the development of 
an individualized intervention to restore immune function and improve health.  
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There is a growing emphasis on the microbiota and its impact on human’s health and 
disease especially the neurobehavioral responses and immune status. The interplay between the 
compositional and functional complexity of human microbiota and neuro-immune systems is 
often described as the brain-gut signaling system. Emergent research has shown that microbiota 
is crucial in regulating immune-inflammatory responses and inducing stress-related changes in 
behavioral and physiological responses (Bailey, 2014; Bharwani et al., 2016).  Multiple factors 
have been identified influences the microbiota-gut-brain axis, including diet, physical activity 
and medication.  Evidence has supported that brain-gut microbiome axis is a promising 
mechanism linking stress, inflammation, and microbiota in human’s health (Cong, Xu, 
Romisher, et al., 2016). This manuscript style dissertation focused on exploring the relationship 
between pain/stress, microbiome and host immunity. The aim is to expand our understanding of 
early life stress and microbiome patterns and their roles in the modification of the immune-
inflammatory processes. 
1.1 Brain-gut microbiota axis  
The concept of the brain-gut-microbiota axis is used to describe the bidirectional 
interaction between the central nervous system and peripheral gastrointestinal (GI) functions. 
This bidirectional communication network enables top-down signaling from the brain to 
influence the motor, sensory and secretory modalities of the GI tract. And conversely, the 
bottom-up signaling from the gut affects brain function, especially hypothalamus and amygdala 
that are devoted to emotion and stress (Carabotti, Scirocco, Maselli, & Severi, 2015; Galley et 
al., 2014).  
The intestinal microbiota is involved in modulating peripheral GI function in several 
different ways, including affecting intestinal permeability, altering mucosal immune function, 
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interfering enteric reflex and entero-endocrine signaling (Mayer et al., 2015). Microbiota and its 
metabolites function somewhat like an endocrine organ and have been found associated with 
inflammatory and autoimmune conditions (Shen & Wong, 2016). The composition and function 
of microbiota has profound effects in the development and maturation of immune cells including 
natural killer T cells and regulatory T cells (Hrncir, Stepankova, Kozakova, Hudcovic, & 
Tlaskalova-Hogenova, 2008; Wei et al., 2010). Dysbiosis also damage the intestinal chemical 
and physical barriers, and impact the function of the immune factors such as secreted soluble 
immunoglobulin A and antimicrobial peptides (Sommer & Backhed, 2013). Evidence also 
suggests that changes in the composition of the gut or dysregulations of the microbial community 
are correlated with anatomy changes in central nerves system and altered brain functions such as 
emotional behaviors and social interactions (Mayer et al., 2015). 
Several body systems are involved in the bidirectional brain-gut communication network, 
including the central nervous system (CNS), the autonomic nervous system (ANS), the enteric 
nervous system (ENS) and the hypothalamic pituitary adrenal axis (HPA) (Cong, Henderson, 
Graf, & McGrath, 2015).  The ANS includes both the sympathetic nervous system and the 
parasympathetic nervous system. It regulates gut function by transmitting the afferent signals 
from the GI lumen through enteric, spinal and vagal pathways to the CNS, and efferent signals 
from CNS to the intestinal wall, targeting on the ENS, muscle layers and gut mucosa. Both 
branches of the ANS affect gut functions including motility, secretion, immune response and 
permeability of the intestine. The ANS also modulates the response of the gut immune cells 
including macrophages and mast cells to luminal bacteria with antimicrobial peptides. 
Additionally, stressful stimuli activate the HPA axis, leading to changes in the intestinal barrier 
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and gut microbiota, which increases gut permeability, allowing for bacterial invasion across 
epithelial barrier, and ultimately leading to systemic effects (Cong et al., 2015). 
1.2 Pain and Stress 
The International Association for the Study of Pain has defined pain as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage or described 
in terms of such damage” ("Pain terms: a list with definitions and notes on usage. Recommended 
by the IASP Subcommittee on Taxonomy," 1979). Stress is defined as “a physical, chemical, or 
emotional factor that causes bodily or mental tension and may be a factor in disease causation” 
(Merriam Webster's Collegiate Dictionary, 1994).  
Studies have shown that pain and stress impact the gut microbial community, and 
modulate the bacterial composition and function (Bailey, 2012). Physical and emotional stress, 
activates HPA and ANS to the intestine and reduces vagal output to the stomach, which is likely 
to change the composition and organizational structure of the gut microbiota, increase 
permeability of the intestinal epithelium, activate immune response in GI system and result in 
alterations of the GI function (Carabotti et al., 2015; Konturek, Brzozowski, & Konturek, 2011; 
O'Mahony, Hyland, Dinan, & Cryan, 2011; O'Mahony et al., 2009). 
Acute procedural pain/stress, even during a very short period, can activate fight-or-flight 
responses, and prepare the organisms for possible infection and injury by stimulating the immune 
system and up-regulating both innate and adaptive immune responses (Dhabhar, 2014). Similar 
to a single acute pain/stress stimulus, prolonged chronic pain/stress has also been found 
associated with suppression of both cellular and humoral immunity in human adults (Segerstrom 
& Miller, 2004). Persistent pain/stress dysregulates innate and adaptive immune responses by 
stimulating pro-inflammatory cytokine, inducing chronic inflammation, and suppressing host 
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immune function (Chapman, Tuckett, & Song, 2008; Dhabhar, 2014). Cumulative pain/stress is 
more detrimental to health outcomes in neonatal infants where neuro-immuno-wiring and gut 
microbiome patterns are under formulation and thus, more easily altered. Persistent pain and 
stress during infancy can cause neuro-behavioral deficits and these alterations may last till 
adulthood (Beauchamp et al., 2008; Grunau, Holsti, & Peters, 2006; Grunau et al., 2009; 
Hermann, Hohmeister, Demirakca, Zohsel, & Flor, 2006). Exposure to prolonged 
painful/stressful events in the NICU has been found to be associated with reprogramming of the 
immune system, including depressed cortisol responses in preterm infants during NICU stay, and 
elevated cortisol level at 8 and 18 months corrected age (Grunau et al., 2007; Grunau et al., 
2005). 
Despite the fact that strong evidence shows uncontrolled pain/stress has destructive 
consequences, particularly in preterm infants, few instruments are available to assess the 
cumulative and persistent pain/stress. Majority of the existent tools are used to assess one-time 
acute pain/stress, which fails to provide a picture of long-term stress levels, especially in 
newborns. Few instruments have been developed to measure cumulative pain/stress, e.g., 
Neonatal Infant Stressor Scale (NISS); developed in Australia (Newnham, Inder, & Milgrom, 
2009), and the generalizability of these tools to the population in the U.S needs to be tested.  
1.3 Human Microbiota 
Microbiota refers to the ecological community of commensal, symbiotic, and pathogenic 
microorganisms that reside in human’s body (Group et al., 2009; Lederberg & McCray, 2001). 
Approximately 3.8·1013 microorganisms live in human beings and play an essential role in 
human health and disease (Davis & Bajaj, 2017; Halfvarson et al., 2017; Maruvada, Leone, 
Kaplan, & Chang, 2017; Sender, Fuchs, & Milo, 2016; Tremlett, Bauer, Appel-Cresswell, 
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Finlay, & Waubant, 2017; Wu & Lewis, 2013; Young, 2017; Zhang & Zhao, 2016). Human 
microbiota has been classified into five types, including bacteria, archaea, protists, fungi, and 
virus. Human microbiota inhabit many human organs and tissue, most particularly the GI system 
(Sender et al., 2016). Microbial community can be considered as an essential organ and benefits 
human in many different ways, including providing essential nutrients such as hormones and 
vitamins to maintain proper function of the human body, metabolizing indigestible compounds 
and fermenting indigestible dietary fiber into short-chain fatty acids (SCFAs), providing physical 
barriers to protect against pathogens, and modifying host immune function and inflammatory 
responses (Boleij & Tjalsma, 2012; Cong, Judge, et al., 2017; Quigley, 2013; Round & 
Mazmanian, 2009; W. Xu et al., 2017). Dysbiosis, the alteration or imbalance of the microbial 
community, disrupts human wellness and leads to disease in many different ways. It has been 
found to be associated with increased risk of colic (Kianifar et al., 2014) and necrotizing 
enterocolitis (NEC) in preterm infant (Cilieborg et al., 2016; Thomas, 2016), and can lead to 
infection, immune disorders (eg. inflammatory bowel disease) (Burcelin, 2016; Jiang et al., 
2015; Marteau, 2009), metabolic syndrome (i.e., diabetes, obesity) (Menni et al., 2017; 
Rozanova, Voevodin, Stenina, & Kushnareva, 2002; Turnbaugh et al., 2009), neurological 
disorders (McKay et al., 2017; Tremlett et al., 2017), and cancer (Loo et al., 2017; Yamamoto & 
Matsumoto, 2016; Zhu, Gao, Wu, & Qin, 2013) later in life. 
1.3.1 Gut Microbiota 
The gut microbiota refers to the aggregation of microorganisms that reside in the GI tract. 
Compared to other parts of the body, the GI tract is the largest habitat for microbes, and it 
harbors 99% of the bacteria in the human body (Sender et al., 2016). The gut microbial 
community is a dynamic developmental ecosystem and the composition changes over time. The 
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colonization begins at birth and is influenced by the delivery mode, milk regimen, and gender 
(Cong, Judge, et al., 2017; Cong, Xu, Janton, et al., 2016; Cong, Xu, Romisher, et al., 2016; 
Thursby & Juge, 2017; P. Xu et al., 2017). Gut microbiome in infants is dominant by 
Actinobacteria and Proteobacteria and with relatively low diversity and a small number of 
operational taxonomic units (OTUs) (Backhed, 2011; Cong, Xu, Janton, et al., 2016; Rodriguez 
et al., 2015). During the first years of life and with the introduction of solid food, the gut 
microbiota gradually shifts, and matures to a community with increased diversity and adult-like 
composition. The gut microbiota in adults is relatively stable and is primarily dominated by 
Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria (Khanna & Tosh, 2014). As the 
individual aging, the abundance of Bacteroidetes increases and becomes dominant in the gut 
microbial community (Rodriguez et al., 2015).  
In addition to the shared changes caused by chronological age, the gut microbiota also 
displays variation among individuals and geographical population (Yatsunenko et al., 2012). Gut 
microbiota pattern is shaped by multiple factors, including colonization early in life, host 
genetics, diet, an individual’s lifestyle, stress, incidence of diseases, and exposure to medications 
(Backhed et al., 2015; Cong, Judge, et al., 2017; Cong, Xu, Janton, et al., 2016; Cong, Xu, 
Romisher, et al., 2016; Dominguez-Bello et al., 2010; Hansen, Gulati, & Sartor, 2010; Karkman, 
Lehtimaki, & Ruokolainen, 2017; Kuang et al., 2017; Moles et al., 2013; Mosca, Leclerc, & 
Hugot, 2016; Tulstrup et al., 2015; W. Xu et al., 2017).  
Gut microbiome plays a vital role in human’s health. Gut bacteria produce enzymes, 
which ferment indigestible carbohydrates and generate short fatty acids, such as acetic, 
propionic, and butyric acids. These short fatty acids provide energy sources to host cell and are 
essential to cellular processes such as gene expression, proliferation, and programmed cell death 
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(Puertollano, Kolida, & Yaqoob, 2014). The microbiome also synthesize essential vitamins such 
as folic acid, Vitamin K and biotin and metabolize bile acids and xenobiotics, which are 
beneficial to the host (LeBlanc et al., 2013; Staley, Weingarden, Khoruts, & Sadowsky, 2017). In 
addition, gut microbiota has been found critical in the epithelial integrity and function. Dysbiosis 
of gut flora may lead to alteration in gastrointestinal motility, colonic epithelial cell homeostasis 
and impaired barrier function (Shi et al., 2017; Sommer & Backhed, 2016).  
Moreover, gut bacteria influence the development of the systemic and intestinal mucosal 
immune systems (Thursby & Juge, 2017). Animal studies have found that germ-free animals 
have extensive deficits in the development of the gut-associated lymphoid tissues, antibody 
production and are more susceptible to certain bacterial infection (Round & Mazmanian, 2009). 
Alteration of the bacterial composition can affect the production and function of several cell 
types including epithelial cells, dendritic cells, and T cells, impact production capacity of 
inflammatory cytokines and lead to inflammation and disease (Hakansson & Molin, 2011; 
Schirmer et al., 2016).  
1.3.2 Microbial translocation 
Microbial translocation is the translocation of microorganisms and their products from 
the GI tract into the systemic circulation. Microbial translocation can occur in healthy individuals 
and increases when there is a dysfunction of the gastrointestinal barrier (Sandler & Douek, 
2012). The alteration of the gut microbiome community causes intestinal mucosal barrier 
damage, GI immune dysregulation, which increases intestinal permeability and allows gut 
bacteria translocated to the bloodstream (Barlow, Yu, & Mathur, 2015; Mathur & Barlow, 2015) 
(Bischoff, 2017; Bouter, van Raalte, Groen, & Nieuwdorp, 2017; Chiriac, Mahapatro, Neurath, 
& Becker, 2017). Increased “leakiness” of the intestinal barrier further causes immune cell 
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activation and up-regulation of pro-inflammatory cytokines and drives immune perturbations and 
persistent systemic inflammation (Dinh et al., 2015). Microbial translocation has been 
recognized as an important pathogenic mechanism in many diseases. Microbial translocation-
related persistent immune activation has been found associated with several infectious diseases 
such as HIV infection and hepatitis (French et al., 2013; Ortiz & Brenchley, 2018). Low-grade 
microbial translocation was also found associated with autoimmune and neurological disorders 
such as diabetes, multiple sclerosis and autism (Aravindhan, Mohan, Arunkumar, Sandhya, & 
Babu, 2015; Emanuele et al., 2010; Mirza & Mao-Draayer, 2017).  
1.4 Immune Responses 
Inflammation is the response of the body to harmful stimuli, such as injury and invasion 
of microorganism. When external stimuli invade the body, the immune system is activated, and 
the immune cells such as macrophages, mast cells, and circulating leukocytes rapidly recognize 
the signal derived from the pathogen invasion or cell damage by pattern recognition receptors 
(PRRs). There are different types of pattern recognition pathways, including pathogen-associated 
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). The receptors 
detect PAMPs and DAMPs, and initiate signaling cascades that trigger the release of 
inflammatory mediators, leads to vasodilation and increased blood flow. The increased 
permeability of blood vessels allows the migration of white blood cells from blood vessels to 
local sites and causes the cellular coagulation (Hakansson & Molin, 2011; J. Liu & Cao, 2016; 
Newton & Dixit, 2012).  
PAMPs refer to the molecules that conserved within the microorganism but are not 
expressed in the host. Most common PAMPs are microbial nucleic acids, the bacterial protein 
flagellin, lipopolysaccharide (LPS), and endotoxin. In contrast, DAMPs are compounds that 
	 10	
released to the surface of the cell following the host cell damage. DAMPs include protein 
DAMPs and non-protein DAMPs. Examples of DAMPs include ATP, uric acid, heat-shock 
protein, the cytokine IL1α, and the calcium-modulated proteins S100A8 and S100A9 
(calprotectin) (Newton & Dixit, 2012). 
Inflammation is categorized as either acute or chronic. Acute inflammation occurs within 
hours following injury and is characterized by an accumulation of neutrophil and eosinophil 
granulocytes (Ward, 2010). Examples of acute inflammation are bacterial infection, the 
breakdown of cancer tumors and allergic reaction.  Chronic inflammation refers to the process 
that involves lymphocytes, macrophages, and plasma cells and may last for months to years. In 
contrast to the resolution of acute inflammation, tissue healing and ongoing destruction occur 
simultaneously in chronic inflammation (Ward, 2010). Examples of chronic inflammation are 
persistent intra-cellular microbial infections (i.e., chronic HIV) and autoimmune disease (i.e., 
lupus). 
Innate and adaptive immunity are two major categories of responses of the immune 
system. Innate immunity is general defense mechanisms that can be activated immediately when 
the stimuli entered into the body. Common elements involved in innate immune response include 
physical barriers such as skin and mucous membranes, substances in the blood, and immune cells 
such as neutrophil granulocytes, macrophages, and natural killer cells. Neutrophil granulocyte is 
one of the most critical factors in innate immune defense. Neutrophils regulate inflammation via 
the release of pro-inflammatory mediators, cytokines, and calprotectin (Rosales, Lowell, 
Schnoor, & Uribe-Querol, 2017). Calprotectin is DAMP with antimicrobial protective properties 
and can initiate and perpetuate the immune response (Smith & Gaya, 2012). 
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 Adaptive immunity is an antigen-specific immune response. It recognizes and 
memorizes specific antigen and produces immune cells and antibodies that are specifically 
designed to attack that antigen. Adaptive immunity consists of B cells that produce antibodies 
and T cells that destroy pathogen-infected cells and produce cytokines that regulate the immune 
system. CD4 T lymphocytes play an important role in both humoral and the cellular part of the 
adaptive immune response. It is essential in protecting the body against pathogens. The depletion 
of the CD4 T lymphocytes is commonly related to the HIV infection and, especially with HIV 
progression and the absence of antiviral treatment (Baker et al., 2008). Dysfunction of the 
adaptive immune system may lead to major infections, and increase patients’ risk of 
complications, morbidity, and mortality. 
The immune responses are influenced by many factors including diet, age, stress, 
medication, and individual’s genetics and medical condition. Recent research has suggested that 
both stress and gut microbiota have a significant impact on an individual’s immune system (El 
Aidy, Dinan, & Cryan, 2014). Dysbiosis of gut microbial community leads to the invasion of 
pathogens to gut mucosa, release factors that disrupt pro- and anti-inflammatory balance, results 
in intestinal inflammation (El Aidy et al., 2014; Forbes, Van Domselaar, & Bernstein, 2016). 
Pathogens and their metabolites have been found associated with disrupted gut barrier function 
and increased gut permeability, which leads to the induction of toll-like receptors, ultimately 
activates immune responses (Carvalho, Aitken, Vijay-Kumar, & Gewirtz, 2012; Dinan & Cryan, 
2012). Microbiota also influences the immune system by regulating the development of 
organized lymphoid structures and the function of immune cells such as T lymph cells 
(Emanuele et al., 2010). Furthermore, persistent pain/stress has been found related to 
dysregulation of innate and adaptive immune responses (Chapman et al., 2008; Dhabhar, 2014). 
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Stress can disrupt the immune function in many pathways, such as stimulating pro-inflammatory 
cytokine and suppressing its capacity to produce antibodies (Segerstrom & Miller, 2004). 
Dysregulated immunity caused by stress and dysbiosis is associated to a number of different 
diseases, such as infection, inflammatory bowel disease, multiple sclerosis, arthritis, lupus, 
asthma and cancer (Forbes et al., 2016; Reiche, Nunes, & Morimoto, 2004; Segerstrom & Miller, 
2004). 
1.5 Overall goal of the dissertation 
Exist research findings have suggested that brain-gut-microbiota axis plays a critical role 
in regulating pain/stress, gut microbiome, and immune responses. Dysfunction of brain-gut 
microbiota has been found associated with several GI and brain disorders (Borre et al., 2014; 
Sekirov, Russell, Antunes, & Finlay, 2010). However, the underlying mechanisms of the 
interplay with each other have not been fully understood. This manuscript style dissertation 
investigated these mechanisms. 
Pain/stress have significant influences on individuals’ physical and psychological-
behavioral health particularly in children (Schneiderman, Ironson, & Siegel, 2005). Exposure to 
prolonged stressors during infancy are associated with delayed neurobehavioral development, 
increased risk for cognitive deficits, mood disorders, aggressive behavioral problems, immune 
dysfunction, and physical and anatomic changes in the central nerves system (Cong, Wu, et al., 
2017; Shaw, 2003). However, the majority of existing instruments were developed to measure 
acute pain using behavioral measures, which may not be able to capture the full effect of stress in 
preterm infants particular those are extremely immature. Study 1 was conducted to begin to 
develop an object instrument to quantitatively measure pain/stress in premature infants in the 
NICU.   
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Antiretroviral therapy (ART) has been a profound success in reducing the mortality and 
morbidity of HIV disease. However, chronic immune dysregulation remains a critical issue in 
HIV disease even in patients under viral suppressive ART treatment. To understand the 
underlying mechanism of long-term humoral immune perturbations, study 2 investigated the 
factors that contributed to the elevated anti-CD4 autoantibody production through brain-gut-
microbiome axis model. The findings suggested that distinct systemic microbiome and levels of 
microbial translocation played a role in anti-CD4 autoantibody production in ART-treated HIV 
disease. 
Preterm infants are vulnerable to severe infections (i.e., neonatal sepsis, necrotizing 
enterocolitis) and lead to up to 40 percent of mortality rate in the United States. Large bodies of 
evidence have indicated that stress (i.e., psychological, environmental and physical) can activate 
immune response, and cause immune dysregulation (Beversdorf, Stevens, & Jones, 2018; Y. Z. 
Liu, Wang, & Jiang, 2017). Early life stress stimulates the release of the proinflammatory 
cytokine, activate the HPA axis (O'Mahony et al., 2009). Elevated glucocorticoid hormone has 
been reported associated with decreases in the intestinal epithelial tight junction protein claudin-
1, impairs epithelium homeostasis and barrier function (Zheng et al., 2017). The changes of 
intestinal barrier lead to the invasion of pathogenic microbes across the mucosal lining and 
activate the inflammation in the gut (Gareau, Silva, & Perdue, 2008; Power, O'Toole, Stanton, 
Ross, & Fitzgerald, 2014). The goal of study 3 was to test the hypothesized mechanism of 
cumulative pain/stress in modulating the gut inflammation among preterm infants. 
1.6 Specific Aims and Hypothesis 
Specific aim for study #1: To develop and validate the Accumulated Pain/Stressor Scale 
(APSS) to quantitatively assessing cumulative pain/stress in the neonatal intensive care unit 
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(NICU). The study 1 was the second stage of the scale development, which aimed to explore 
nationwide neonatal clinicians’ perceptions regarding acuity and severity of each 
painful/stressful event in the NICU and to gather additional data to validate the APSS.  
Specific aim of study #2: To investigate the underlying mechanisms of long-term 
humoral immune perturbations in HIV-infected patients. We hypothesized that microbial 
translocation of specific bacterial strains might play a role in B cell activation and anti-CD4 
autoantibody production. 
Specific aim of study #3: 1) To describe the gut inflammation in preterm infants during 
the first four weeks of life; 2) To explore the contributing factors that are associated with gut 
inflammation; and 3) To examine the association between cumulative stress in early life and gut 
inflammatory among preterm infants. We hypothesized that preterm infants with a higher score 
of cumulative pain/stress would have a higher level of Fecal calprotectin. 
1.7 Conclusion 
Dysregulation of immune function has a significant impact on human health and has been 
found related to infection, neurodegeneration, auto-immune disease and tumor genesis. The 
findings of each study presented in this dissertation will contribute to the understanding of the 
etiology and mechanism of immune activation through brain-gut-microbiota axis. Knowledge 
gained from the study will help to develop an individualized approach to restore immune-
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Stressor Scale (APSS) in
NICUs: ANational Survey
--- Wanli Xu, BS, MS, RN, Stephen Walsh, ScD,
and Xiaomei S. Cong, PhD, RN
- ABSTRACT:
High-risk neonates experience numerous painful/stressful proced-
ures daily in neonatal intensive care units (NICUs). Accumulated pain
and stress have a detrimental impact on infants’ neurodevelopment.
Few valid tools are available to measure accumulated pain/stressors
among NICU infants. The aim of this study was to obtain nurses’ per-
ceptions about severity and acuity levels regarding each painful/
stressful procedure that infants may experience in the NICU. The data
will support developing a new instrument, the Accumulated Pain/
Stressor Scale (APSS) in NICUs. A nationwide online survey was con-
ducted through the U.S. National Association of Neonatal Nurses
membership. Respondents were asked to rate the perceived severity of
pain/stress associated with 68 procedures using a 5-point Likert scale
and to categorize pain/stress as acute or chronic. Modal values were
used to determine summary rankings among the procedures. Eighty-
four neonatal nurses completed the survey. Among 68 procedures,
nearly all were rated as painful/stressful to some degree. Five pro-
cedures (7%) had a modal value of five (extremely painful/stressful),
nine (14%) had a value of four, 20 (29%) had a value of three, 30 (44%) a
value of two, and four (6%) had a value of one (not painful/stressful).
Forty-four procedures (65%) were perceived as acute, six (9%) as
chronic, and 18 (26%) as both acute and chronic. Nurses’ perceptions
of pain severity and acuity regarding procedures in NICUs varied
somewhat. Further studies are needed in developing and validating
the scale. The development of the APSS can quantitatively measure the
accumulated neonatal pain/stress.
! 2016 by the American Society for Pain Management Nursing
BACKGROUND
Evidence has established that newborn infants, including prematurely born in-
fants, have the ability to perceive and experience pain. Moreover, because of
immaturity of the descending pathways that inhibit pain impulses, preterm
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neonates have lower tolerance for painful procedures
than full-term infants, potentially leading to more se-
vere consequences (Slater et al., 2010). In the high-
technology, neonatal intensive care unit (NICU) envi-
ronment, preterm infants are more likely to receive
painful and stressful stimuli and, because of extended
hospitalization, tend to receive it over a longer dura-
tion. On average, preterm infants experience 12-16
painful procedures per day (Carbajal et al., 2008).
Growing concerns have been raised about accumu-
lated and unmanaged pain/stress exposure in early
life and its long-term, adverse consequences on the in-
fant brain and neurodevelopment.
Vulnerable infants exposed to intense, repeated,
or prolonged painful/stressful procedures in early life
are likely to have altered pain pathways and thresh-
olds, altered programming of stress systems, and
impaired neurobehavioral outcomes, including cogni-
tive, memory, and behavioral deficits, compared with
full-term peers. These deficits may persist into adoles-
cence and adulthood (Beauchamp et al., 2008;
Grunau, Holsti, & Peters, 2006; Grunau et al., 2009;
Hermann, Hohmeister, Demirakca, Zohsel, & Flor,
2006). When neonatal rats experience persistent
peripheral inflammation, similar to multiple heelstick
procedures given to human neonates, their spinal
neuronal circuits exhibit changes in nociceptive
primary afferent axons and show altered responses
to sensory stimulation during adulthood (Bhutta
et al., 2001; Ruda, Ling, Hohmann, Peng, &
Tachibana, 2000). Similarly, repetitive or cumulative
exposure to pain and stress is believed to
permanently alter a human newborn’s neuronal and
synaptic organization (Anand & Scalzo, 2000;
Fitzgerald & Beggs, 2001). More seriously, unrelieved
excessive pain/stress can alter the structure and
function of the developing brain in preterm infants
through, for example, reduction of white and
subcortical gray matter structures during maturation
(Brummelte et al., 2012). These pain/stress exposures
may be related to altered IQ in school-age children that
is mediated by brain microstructural changes (Vinall
et al., 2014). Strategies for assessing and managing cu-
mulative pain/stress in the early life stage remain
largely under-investigated and urgently need to be
addressed.
More than 40 neonatal pain measurement tools
currently are available for research and clinical use,
but no single tool has been established as the ‘‘gold
standard.’’ Additionally, the majority of instruments
were developed to measure acute pain across a short
time period using physiological and behavioral cues,
such as crying, facial expressions, heart rate variation,
increased respiration, and decreased oxygenation
(Cong, McGrath, Cusson, & Zhang, 2013), rather
than directly quantifying cumulative pain and stress
(Ranger, Johnston, & Anand, 2007).
Capturing bio-behavioral response to a painful
procedure is challenging because the hypothalamic-
pituitary-adrenal (HPA) axis in preterm neonates is
not fully developed and physiological cues may not
be displayed because of extreme immaturity
(Newnham, Inder, & Milgrom, 2009). One study found
that only 20% of extremely premature infants cry dur-
ing a heel stick procedure (Gibbins et al., 2008a).
Meanwhile, some physiological and behavioral indica-
tors (e.g., heart rate and crying), may be nonspecific
for pain and could be associated with other conditions,
such as hunger or fatigue. Factors such as severity of
illness, gestational age, frequency of and time since
previous painful procedures, and medication use also
may affect the ability of preterm infants to respond
and could make behavioral variables ineffective in de-
tecting neonatal pain (Gibbins et al., 2008b; Hatfield
& Ely, 2015; Stevens et al., 2007).
These ambiguities leave neonatal nurses chal-
lenged by the issue of pain assessment in NICUs.
Nurses working in NICUs have widely reported (e.g.,
34.7% in the U.S. and 57.5% in China) that the pain
assessment tools adopted in their units are inaccurate
for measuring neonatal pain (Cong et al., 2014).
Compared with acute pain, signs of repeated or cumu-
lative pain tend to be more subtle in preterm infants,
leading to under-recognition and undertreatment
(Ranger et al., 2007). Young preterm infants may not
display ‘‘appropriate’’ signs of pain response when
they experience persistent painful or stressful proced-
ures because they lack the energy reserves to express
bio-behavioral responses (Ranger et al., 2007) or
because the NICU experience has already led to
abnormal brain development and to hypersensitivity
to pain stimuli (Ranger & Grunau, 2014).
To determine the impact of repeated and cumula-
tive pain and to provide an evidential basis for its treat-
ment, NICU infants need to be monitored closely. The
only tool that the authors found for assessing cumula-
tive pain/stress in infants that is specifically targeted
to the NICU setting is the Neonatal Infant Stressor Scale
(NISS) developed in Australia by Newnham et al.
(2009). The NISS provides a systematic way to identify
and quantify infant stress. It lists 68 procedures and at-
taches a severity level to each one. However, in using
the NISS, the authors found that it does not cover
many painful events/stressors that occur as part of
standard practice in NICUs in the United States.
To assess quantitatively and more accurately the
extent and severity of pain/stress that infants experi-
ence in NICUs in the United States, the authors of
355Pain/Stressor Scale in NICUs
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this paper developed the Accumulated Pain/Stressor
Scale (APSS) in NICU. Because it is difficult to differen-
tiate pain and stress in very preterm infants
(Brummelte et al., 2015; Grunau et al., 2013), the
authors use the term ‘‘painful/stressful’’ to
characterize the full spectrum of events that can
cause pain and produce stress in the neonatal
population.
The initial version of the APSS consisted of 62
items (unpublished data) within nine categories of
painful/stressful events potentially experienced by
the NICU infants. The nine categories included blood
draw, feeding, imaging, infection, peripheral venous
access, central venous access, surgery, respiratory,
and ‘‘miscellaneous.’’ A focus group study was conduct-
ed to examine clinicians’ perceptions regarding the
concept of accumulated pain/stress and to obtain
expert judgment of the content validity of the initial
APSS scale. Nine neonatologists and five neonatal
nurses were recruited from a level IV NICU (the high-
est level of NICU, with capacities to provide surgical
repair of complex congenital or acquired conditions)
in the northeastern United States and participated in
the focus group discussion and completed a survey.
Based on results from the focus group (unpublished),
the APSS then was revised to a 68-item scale.
The current study is the second stage of the scale
development, which reports findings from an evalua-
tion of this revised, 68-item instrument. The objectives
were to access a national sample of neonatal clinicians,
to explore their perceptions about the acuity and
severity of virtually all individual painful/stressful
events that occur in NICUs in the United States, and
to use that information to further document the valid-
ity of the APSS.
METHODS
Design
A descriptive, cross-sectional survey design was used
in the study. American neonatal nurses were recruited
through the National Association of Neonatal Nurses
(NANN) webpage. Inclusion criteria for the partici-
pants were registered nurses over 18 years of age, En-
glish speaking, and working in a NICU setting in the
United States at the time of survey.
Instrument
The survey questionnaire consisted of 68 painful/
stressful procedures and events that commonly are
experienced by neonates in the NICU. The procedures
were grouped into 9 categories, including daily care,
feeding, imaging, blood draw, peripheral venous ac-
cess, central venous access, respiratory care, surgeries
and major procedures, and infection. The participants
were asked to classify each of the pain/stressors as
acute, chronic, or both, and to use a numerical scale
to indicate the severity level of each pain/stressor
based on the participant’s experience, knowledge,
and judgment (1 ¼ not painful/stressful; 2 ¼ a little;
3 ¼ moderate; 4 ¼ very; and 5 ¼ extremely painful/
stressful). Survey respondents were instructed to
draw conclusions from their experiences or memories
of the NICU patient population rather than from the
experiences of any particular infant.
Procedures
The study protocol was approved by the Institutional
Review Board of the corresponding author’s home
institution. The survey was uploaded and administered
electronically using Qualtrics Survey Software, Version
2015 (Provo, Utah). NANN members were e-mailed an
invitation letter with a link to the Qualtrics survey
through the NANN website. The information sheet
with informed consent was posted on the survey web-
site as the first question so that the potential partici-
pants were able to select ‘‘yes’’ or ‘‘no’’ to
acknowledge that they had read the information sheet
and gave informed consent before they could continue
with the survey questionnaire. Demographic informa-
tion was collected at the end of the survey question-
naire. After the initial invitation e-mail, two reminder
e-mails were sent 10 days apart. The survey remained
available for 30 days following the date of the initial
e-mail to the participants. When participants
completed the survey, their data were secured within
a password-protected account. Once the survey was
closed, the data were downloaded for statistical
analysis.
Statistical Analysis
Survey data were analyzed using the R statistical soft-
ware package (R 3.22). Descriptive statistical methods
were used to summarize responses. This included
calculating the mode and the average deviation from
the mode (ADFM) for the acuity classification and for
the severity ranking for each APSS item. The ADFM is
the average of the absolute deviations from the
mode. It quantifies dispersion or variability and can
be used to describe agreement among the participants
scoring each item. Correlation coefficients also were
computed to evaluate associations among the severity
of pain/stress that nurses rated for each procedure and
their ages, educational levels, years of NICU experi-
ence, and highest NICU level in which they had
worked.




Eighty-four neonatal nurses from the United States
participated in the national survey. The majority
were female (98.8%), non-Hispanic white (95.2%),
had a baccalaureate or higher degree (89.2%), and
had worked in a Level III (capable of providing
comprehensive care for infants born<32 weeks’ gesta-
tion and weighing <1500 g and critically ill infants) or
Level IV NICU (96.4%). The mean age of the neonatal
nurses was 50.2 " 10.8 years, with an average of
22.9 " 10.9 years working experience in the NICU.
Table 1 summarizes demographic characteristics of
the participants.
Acuity of Perceived Pain/Stressors
Figure 1 depicts the acuity classification based on the
mode of the acuity classifications for each item.
Forty-four (64.7%) painful/stressful events were
considered to be acute, including events from 8 of
the 9 categories: blood draw, feeding, imaging, periph-
eral venous access, central venous access, procedures,
respiratory, and miscellaneous. Six (8.8%) events were
considered to be chronic: orogastric tube in situ
(feeding), nasogastric tube in situ (feeding), peripheral
venous access in situ (peripheral venous access),
peripherally inserted central catheter (PICC) in situ
(central venous access), nasal cannula (respiratory),
and high frequency oscillatory (HFO)/jet ventilator
with sedation (respiratory). Eighteen (26.5%) events
from 6 categories (blood draw, feeding, infection, pro-
cedure, respiratory event, and peripheral venous ac-
cess) were considered to be both acute and chronic.
The ADFM for the acuity of each event ranged
from 0.02 to 0.93. The events with lowest ADFM (rep-
resenting relatively high agreement among survey re-
spondents) included cardiac echo (0.02), CAT scan
and magnetic resonance imaging (MRI) (0.02), electro-
cardiogram (ECG) (0.08), ultrasound (0.10), and pe-
ripheral IV insertion with single attempt (0.11),
whereas the ones with highest ADFM (representing
lowest agreement) included peripheral IV insertion
with multiple attempts (0.93), nasal continuous posi-
tive airway pressure (NCPAP) prong insertion (0.92),
local infection (0.90), PICC line insertion with multiple
attempts (0.87), and learning to bottle feed (0.83).
Severity of Perceived Pain/Stressors
Figure 1 also represents the mode and ADFN of the
severity level of pain/stress for each event. Four
(4.8%) events were ranked most frequently as 1 on
the 5-point Likert scale (1 ¼ not painful/stressful;
5 ¼ extremely painful/stressful), 30 (35.7%) events as
level 2, 20 (23.8%) events as level 3, 9 (10.7%) events
as level 4, and 5 (6.0%) events as level 5. The four
events that were scored as not painful/stressful were
learning to breastfeed, oxygen tent, PICC line in situ,
and removal from bed (wrapped). The events that
were considered the most painful/stressful included
gastroschisis abdominal content reduction, lumbar
puncture, recovering from major surgery, chest tube
insertion, and intubation with multiple attempts.
The ADFM for severity score ranged from 0.35 to
0.99 (Fig. 1). Examples of the events with lowest
ADFM (and so with the strongest agreement among re-
spondents) were oxygen tent (0.35), nasal cannula
(0.35), cardiac echocardiography (0.37), chest tube
insertion (0.38), and nasogastric/orogastric tube
removal (0.38). Examples of the events with highest
ADFM (and so the weakest agreement) were lumbar
puncture (0.99), gastroschisis abdominal reduction
(0.92), chest tube removal (0.85), tourniquet use for
PICC line insertion (0.85), and conventional ventila-
tion without sedation (0.77).
TABLE 1.
Demographic Characteristics of Responding
Neonatal Nurses (N ¼ 84)
Demographic
Characteristics Frequency Percentage (%)










Sex (n ¼ 84)
Male 1 1.2
Female 83 98.8
Race (n ¼ 82)
White 80 97.6
Asian 2 2.4
Ethnicity (n ¼ 82)
Hispanic 2 2.4
Non-Hispanic 80 97.6





Level of NICU (n ¼ 84)
Level II 3 3.6
Level III 43 51.2
Level IV 38 45.2
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For each participant, the mean severity score of all
the events within each of the 9 categories was calcu-
lated. Spearman correlations between the mean score
of each category and the demographic characteristics
then were computed. The results showed no signifi-
cant correlation between the mean perceived severity
of any category and participants’ age, years of experi-
ence as a neonatal nurse, or level of education.
01 Learning to breastfeed
02 Conventional ventilator with sedation
03 Learning to bottle−feed
04 NCPAP manipulation
05 Local Infection
06 IV blood draw, multiple
07 Chest tube indwelling (water seal/gravity)
08 NPO (Nothing by mouth)
09 Multiple heelsticks
10 Conventional ventilator without sedation
11 Insertion, multiple attempts_PICC
12 Recovering from minor surgery
13 Arterial blood draw, multiple
14 Systemic infection
15 HFO/jet ventilator without sedation
16 Recovering from major surgery
17 Intubation, multiple attempts
18 Gastroschisis abdominal content reduction
19 PICC in situ
20 Nasal cannula
21 OG tube in situ
22 Peripheral IV in situ
23 NG  tube insertion
24 HFO/jet ventilator with sedation
25 Oxygen tent
26 Removal from bed, wrapped
27 Cardiac echo
28 NG/OG tube removal
29 Position change
30 Mouth care




35 Weight (isolette/warmer/open crib)
36 Flushing for patency_IV
37 NG  tube in situ
38 Removal of PICC
39 OG  tube insertioin
40 ECG
41 Removal of monitor leads
42  Chest or Addominal X−ray
43 Phototherapy
44 Lateral abdominal X−ray
45 CT/MRI
46 Bathing
47 Removal from bed, unwrapped
48 Tourniquet use_PICC
49 IV blood draw, single
50 Single heelstick
51 Insertion, single attempt_PICC
52 Oral/nasal suctioning
53 Insertion, single attempt_IV
54 Urinary catheterization
55 NCPAP prong insertion
56 Suctioning from endotracheal tube
57 Removal of tape/dressing_PICC
58 Removal of tape/dressing_IV
59 Tourniquet use_IV
60 Intubation, single attempt
61 Removal of endotracheal tube tape
62 Chest tube removal
63 Insertion, multiple attempts_IV
64 Arterial blood draw, single
65 Circumcision
66 Eye exam
67 Chest tube insertion
68 Lumbar puncture
1 2 3 4 5













FIGURE 1. - Severity and acuity of each procedure. The graph showsmode (dot) and average deviation of mode (error bar) of
the severity of each painful/stressful procedure on a 5-point scale. The procedureswere grouped into acute (red), both acute
and chronic (green), and chronic (blue) based on the mode of acuity.
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However, there was a correlation between the highest
NICU level where a participant had worked and the
mean perceived pain/severity scores assigned to the
blood draw category (r ¼ 0.249, p < .05). Correlations
between the mean score assigned to the blood draw
category and the other 8 pain/stress categories were
not statistically significant.
Summarizing Pain/Stressors Using the APSS
As explained above, the 68 painful/stressful events and
procedures included in the APSS are classified into
nine caregiving categories. Based on the survey results,
within the nine categories, each item was assigned to a
pain/stress severity level and to one of three acuity
levels, acute (A), both acute and chronic (B), and
chronic (C) (Table 2). To document infant pain/
stressors using the APSS, clinicians can tally the acute
(A) procedures, and tally and record the hours/minutes
of both acute and chronic (B), or chronic (C) events,
depending on the course of the events for each shift.
The recorded frequency or duration of each event
can be weighted through multiplication by the as-
signed pain severity level for that event. A total score
for each acuity level (A, B, and C) can be calculated
for each day by summing the weighted frequency or
duration for each acuity level.
DISCUSSION
Neonatal nurses participating in this national survey
perceived that almost all (64 of 68) of the procedures
in the APSS were painful and stressful to neonatal in-
fants to some extent. On average, the events and pro-
cedures included in the daily care, feeding, and
imaging categories were perceived as only ‘‘a little pain-
ful/stressful.’’ In contrast, procedures related to blood
draw and medical procedures were considered ‘‘very
painful/stressful.’’ These results are consistent with
findings from Newnham’s study that procedures in
nutrition, radiology, and nursing are perceived as less
stressful, while medical procedures and surgery are
perceived as most stressful (Newnham et al., 2009).
No correlations were found between nurses’ de-
mographic characteristics and the perceived pain/
stress level for each category, except the relationship
between the highest NICU level in which a nurse
had worked and the nurse’s perception of pain/stress
level for blood draw. Nurses who have taken care of
high-risk infants in a higher-level NICU viewed blood
draw procedures as having a higher level of pain, a phe-
nomenon that may be related to their experience or
pain management training in such units.
Events that were classified as chronic by neonatal
nurses tended to be less painful/stressful, with the
modal severity level generally falling at 1 (not pain-
ful/stressful) or 2 (a little painful/stressful). Seventeen
of 68 events were perceived as both acute and chronic
by clinicians. One of the reasons for this result may be
that there is still no established definition of chronic
pain in the neonatal population (van Dijk & Tibboel,
2012). The concept of ‘‘pediatric chronic pain’’ has
been defined as persistent or recurrent discomfort
that lasts longer than an expected course of acute
illness or injury, usually longer than 3 to 6 months
(American Pain Society, 2012). However, this criterion
usually cannot be applied to a neonatal population
because the neonatal period is usually shorter than
3 months for most infants.
Although several studies have been conducted to
conceptualize neonatal chronic pain, a consensus re-
mains elusive (Pillai Riddell et al., 2009; van
Ganzewinkel, Anand, Kramer, & Andriessen, 2014).
Pillai Riddell’s study listed potential examples of
chronic pain in infancy, including repetitive acutely
painful procedures such as cardiac patients with
multiple surgeries, infants exposed to daily heel
lances, and needle sticks (Pillai Riddell et al., 2009).
van Ganzewinkel also concluded that experiencing
‘‘daily episodes of continuous or recurrent pain sensa-
tions’’ constitutes a potential etiology for chronic pain
(van Ganzewinkel et al., 2014). The authors’ findings
are consistent with those of previous studies in that
some events, including multiple heelsticks and other
blood draws, were perceived as both acute and
chronic because of initial high severity and long
duration.
Agreement varied on the severity level perceived
by neonatal nurses for individual painful/stressful
events. Procedures that were viewed as less painful/
stressful, such as oxygen tent, nasal cannula, cardiac
echocardiography, and nasogastric/orogastric tube
removal, tended to have higher agreement (small
ADFM) among nurses, whereas procedures that were
viewed as more painful/stressful, such as lumbar punc-
ture, gastroschisis abdominal reduction, and conven-
tional ventilation without sedation tended to have
higher disagreement. This could be explained by the
fact that no specific clinical circumstances for events
in the APSS were provided to the survey respondents.
In an open-ended question included at the end of the
survey, 24 of the 84 participants commented on the
lack of specific circumstances of the procedures
when rating perceived pain/stress experienced by ne-
onates. Multidimensional factors that may influence
potential pain/stress responses and consequences
include neonates’ state and health conditions, the pro-
fessional experience of the clinician who performs the
procedure, whether comfort measures or analgesia is
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given, and the diverse pain management techniques
and protocols used in different units and hospitals. In
light of the results, the more severe painful/stressful
a procedure is, the more varied the clinical and care-
giving factors that affect pain/stress assessment and
outcomes. To prevent harmful long-term effects on in-
fant health, clinicians need to address management of
different levels of painful/stressful procedures in the
NICU.
One of the limitations of this study is a failure to
account fully for variability in pain/stress experience
across different neonates’ conditions and across
different institutional contexts. However, the majority
of existing pain measurement tools applied to the
neonatal population, including assessments based on
physiological and behavioral cues, has the same limita-
tion (Krechel & Bildner, 1995; Newnham et al., 2009;
Schiavenato et al., 2013; Stevens, Johnston,
Petryshen, & Taddio, 1996). The current study
attempted to moderate this limitation by using a
national sample of NICU nurses in the expectation
that including a diverse group of respondents would
enhance validity and generalizability of the APSS.
Differences in perceived pain/stress levels for each
item that may be due to contextual factors were
quantified and the mode was used to represent the
severity level of each event under the majority of
circumstances.
Another way in which the present study failed to
account for differences in how neonates experience
pain/stress in the NICU setting is that the survey ques-
tionnaire did not attempt to assess variation in nurses’
perceptions of pain/stress among different postcon-
ceptional age groups. Mixed findings have been re-
ported regarding the relationship of preterm infants’
gestational and postnatal ages and their bio-
behavioral pain responses (Sellam, Cignacco, Craig, &
Engberg, 2011). In one recent study, an infant’s post-
menstrual age was not found to be associated with
any kind of behavioral or physiological pain responses
(Sellam, Engberg, Denhaerynck, Craig, & Cignacco,
2013). Analogously, Newnham’s study showed that
the stress levels that were perceived by clinicians
among different postconceptional age groups (<28,
28-32, and 32-37 weeks, respectively) were similar
(Newnham et al., 2009).
Pharmacological and nonpharmacological inter-
ventions also are factors that affect the severity of
each painful procedure and their roles as potential
moderating factors were not reflected in the APSS.
Pain interventions in the NICU still are not consistently
used in clinical practice because of multiple factors,
such as side effects of opioid medication, lack of stan-
dard pain protocols, and variability in clinicians’
individual practices (Gibbins et al., 2015; Green,
Darbyshire, Adams, & Jackson, 2014; Stevens et al.,
2011). Therefore, further study is needed to calibrate
the severity of painful events experienced by infants
with concurrent administration of analgesic
interventions.
Assessing cumulative pain and stress is critical and
necessary in neonatal care given the strong association
between repeated painful/stressful procedures in early
life and subsequent adverse neurodevelopmental out-
comes in preterm infants (Grunau, 2002; Provenzi
et al., 2015). However, existing pain assessment tools
mostly focus on acute, one-time pain events. To the au-
thors’ knowledge, only two instruments currently in
use attempt to evaluate cumulative pain and stressors,
the Neonatal Infant Stressor Scale (Newnham et al.,
2009) and the Procedural Load Index (Schiavenato
et al., 2013). Both tools were developed using experts
recruited from local areas, which may limit their gener-
alizability to NICUs in United States.
Implications for Nursing Practice and Research
This study describes the perception of pain intensity
for the most commonly encountered procedures/
events in NICUs and uses this information as part of
the validation process for the APSS, an instrument de-
signed to quantify cumulative pain/stress experienced
by NICU infants. Based on the results, NICU nurses
should be aware of the level of pain associated with
each procedure/event as well as the cumulative pain/
stress that infants experience daily. When sufficiently
validated, the APSS scale will provide nurses guidance
in delivering pain management for each infant and in
advocating for infants to avoid unnecessary painful
clinical procedures. Awareness of cumulative pain/
stress scores also will provide NICU nurses the ability
to identify infants with increased risk of adverse neuro-
behavioral development and to offer comforting mea-
sures, such as skin-to-skin contact, to promote more
favorable developmental outcomes.
Existing evidence shows that cumulative pain/
stress is strongly predictive of infants’ neurobehavioral
development. However, the lack of an established and
accurate assessment tool increases the difficulty of
future research exploring the undesirable conse-
quences resulting from cumulative pain/stress or
demonstrating the benefits of protective strategies
that control or compensate for it. This study provides
researchers a new approach for measuring cumulative
pain/stress. With further validation, the APSS scale
should be able to guide clinical practice for individual
NICU infants and to support research that more
conclusively documents effects of cumulative
360 Xu, Walsh, and Cong
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pain/stress in preterm infants and the effectiveness of
protocols for its management.
CONCLUSION
The new APSS scale will provide a systematic tool for
evaluating cumulative pain/stress experienced by pre-
term infants in NICUs. By documenting pain/stressors
using the APSS, clinicians can calculate the total fre-
quency of acute (A) events and weighted scores for
the severity of those events and the duration of both
acute and chronic (B) or chronic (C) events, as well
as durations that are weighted by severity. This infor-
mation can guide the delivery or pain management
and patient care, promoting neurodevelopmental out-
comes later in life. Future studies are needed to further
validate the APSS, especially expert judgment that
addresses the impact of procedures/events with highly
variable classifications by NICU nurses concerning
chronicity or severity. In addition, larger studies need
to be conducted applying the APSS scale in infant pop-
ulations to test the reliability and validity of the instru-
ment and, when necessary, to modify it in order to
enhance its accuracy. Cut-off points for the scale that
predict developmental consequences will also need
to be explored and tested. With further support from
the evidence, the APSS will be used to guide clinical
pain practice and to support research into the effects
of pain and its management.
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Microbial signals have been linked to autoantibody induction. Recently, we found that purified 
anti-CD4 autoantibodies from the plasma of chronic HIV-1-infected patients under viral-
suppressed antiretroviral therapy (ART) play a pathologic role in poor CD4+ T cell recovery. 
The purpose of the study was to investigate the association of systemic microbiome and anti-
CD4 autoantibody production in HIV. Plasma microbiome from 12 healthy controls and 22 HIV-
infected subjects under viral-suppressed ART were analyzed by MiSeq sequencing. Plasma level 
of autoantibodies and microbial translocation (LPS, total bacterial 16S rDNA, soluble CD14, and 
LPS binding protein) were analyzed by ELISA, limulus amebocyte assay, and qPCR. We found 
that plasma level of anti-CD4 IgGs but not anti-CD8 IgGs was increased in HIV+ subjects 
compared to healthy controls. HIV+ subjects with plasma anti-CD4 IgG > 50 ng/mL (high) had 
reduced microbial diversity compared to HIV+ subjects with anti-CD4 IgG £ 50 ng/mL (low). 
Moreover, plasma anti-CD4 IgG level was associated with elevated microbial translocation and 
reduced microbial diversity in HIV+ subjects. The Alphaproteobacteria class was significantly 
enriched in HIV+ subjects with low anti-CD4 IgG compared to patients with high anti-CD4 IgG 
even after controlling for false discovery rate (FDR). The microbial components were different 
from the phylum to genus level in HIV+ subjects with high anti-CD4 IgGs compared to the other 
two groups, but these differences were not significant after controlling for FDR. These results 
suggest that systemic microbial translocation and microbiome may associate with anti-CD4 





Chronic inflammation or immune dysfunction has been a critical issue in human 
immunodeficiency virus (HIV) disease even in patients under viral suppressive antiretroviral 
therapy (ART). ART significantly suppresses HIV viral replication, improves immune function, 
and decreases morbidity and mortality in HIV disease 1,2. However, a substantial number of 
patients fail to reconstitute their peripheral CD4+ T cell counts even after long-term viral-
suppressive ART treatment, and exhibit increased risks of complications, morbidity and 
mortality 3-7. Previous studies have shown that thymic and lymphatic fibrosis, low nadir CD4+ T 
cell counts, sustained increases in inflammation, and microbial translocation may account for 
patients with poor CD4+ T cell recovery under viral suppressive ART treatment 5,8-21. However, 
the exact mechanism governing poor CD4+ T cell recovery is still unknown. In our recent work, 
we studied the anti-CD4 autoreactive IgGs purified from plasma of ART-treated aviremic 
patients with peripheral CD4+ T cell counts less than 350 cells/µL. Our study has shown that 
anti-CD4 autoreactive IgGs induce CD4+ T cell death through antibody-mediated natural killer 
(NK) cell cytotoxicity in vitro, suggesting that anti-CD4 autoantibodies play a role in blunted 
CD4+ T cell reconstitution after ART treatment 22. Consistently, we have found that purified NK 
cells from patients with blunted CD4+ T cell recovery were enriched in cytotoxic cells and were 
able to mediate uninfected CD4+ T cell death ex vivo 23. 
 
Prior to ART treatment, HIV infection results in significant B cell depletion, especially memory 
B cell depletion, B cell hyperactivation and heightened plasma levels of autoantibodies, as well 
as impaired vaccine responsiveness 24-28. These B cell perturbations cannot be completely 
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explained by the lack of contribution from CD4+ T cells; B cell intrinsic defects have been 
observed 29,30. For example, our previous work has shown that purified B cells from HIV-
infected subjects had reduced proliferation capacities in response to toll-like receptor (TLR) 9 
ligand stimulation compared to B cells from healthy controls in vitro 30. Another study from 
Moir’s group reported that purified B cells from HIV-infected patients had reduced antigen-
presenting function compared to B cells from healthy controls when co-culturing with purified T 
cells from the same healthy donors 29. These results suggest B cell intrinsic dysfunction in HIV 
disease. Furthermore, B cells have been reported activated even after long-term viral-suppressive 
ART treatment, which may account for inconsistent serologic antibody responses and cellular 
responses in patients given seasonal influenza vaccination 31. 
 
The underlying mechanisms of long-term humoral immune perturbations in HIV-infected 
patients, despite undergoing ART treatment, are still largely unknown. The fecal microbiota and 
microbial translocation from the gastrointestinal (GI) tract to systemic circulation have been 
recently investigated as a major driver of immune perturbations and persistent systemic 
inflammation in HIV disease 32-35. Increased intestinal permeability due to mucosal barrier 
dysfunction, GI immune dysregulation and/or altered intestinal microbiome are considered to be 
significant factors related to microbial translocation and HIV pathogenesis. Differences in fecal 
microbiome in HIV-infected patients versus healthy controls are associated with systemic 
inflammation 32. Mechanistically, microbial products such as TLR ligands can induce 
autoantibody production and may play a pathogenic role in autoimmune diseases 36-38. Increased 
systemic microbial translocation and its associated inflammation may result in B cell 
hyperactivation and perturbation in HIV disease. After long-term repeated stimulation by low 
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concentrations of TLR ligands (compared to one dose and high concentration as vaccine 
adjuvants) and other microbial products released from the gut 24-26,39, B cells may be polyclonally 
activated as reflected by increased total IgM and IgG 26,40.  
 
 
In the current study, we hypothesize that microbial translocation of specific bacterial strains may 
play a role in B cell activation and anti-CD4 autoantibody production. We, therefore, investigate 
systemic bacterial microbiome, the magnitude of microbial translocation, and plasma anti-CD4 
autoantibodies in HIV+ subjects under long-term viral suppressive ART treatment. 
 
Methods 
Study Design, Subjects, and Data Collection 
This study was approved by the Institutional Review Board at Medical University of South 
Carolina. All methods were performed in accordance with the relevant guidelines and 
regulations. All participants provided written informed consents. In the present study, 12 healthy 
volunteers and 22 HIV+ ART-treated aviremic (plasma HIV RNA < 50 copies/mL) patients were 
enrolled. The clinical characteristics of participants are shown in Table 1.  
 
Inclusion and exclusion criteria 
All participants were age 18 years and older. All patients had documented HIV infection and 
were receiving a stable antiretroviral regimen with plasma HIV RNA < 50 copies/mL more than 
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two years prior to study entry. Transient viremic blips did not exclude participation if flanked by 
viral levels below detection limits. Exclusion criteria included pregnancy, breast-feeding, 
surgery, chemotherapy, inflammatory bowel diseases, and uses of steroids more than 10 mg per 
day for more than 120 days or uses of antibiotics within 14 days prior to enrollment. 
 
ELISA for detection of anti-CD4 IgGs and anti-CD8 IgGs 
 
Human soluble CD4 protein (sCD4, Progenics Tarrytown, NY) or human soluble 
CD8B/P37/LEU2 protein (sCD8, Sino Biological Inc. Beijing, China) were diluted at the 
concentration of 16 µg/ml and added to microtiter wells, and incubated at 4°C overnight. 
Microwells were washed three times with phosphate buffered saline wash buffer (PBS with 0.1% 
Tween 20), and then blocked with PBS containing 3% bovine serum albumin (BSA) for 120 min 
at 37°C. Plasma was diluted 1:40 in PBS containing 3% BSA and 100 µl of the dilution were 
added to the wells. The plate was incubated at room temperature for 60 min. Biotin-labeled goat 
anti-human IgG was added at 1:5000 dilution in PBS containing 3% BSA. The plate was then 
incubated for 60 min at room temperature. Horseradish peroxidase conjugated streptavidin 
(HRP-Streptavidin) was added at a 1:1000 dilution in PBS containing 3% BSA, and then 
incubated for 30 min at room temperature. After washing, 100 µl 2, 2'-Azino-di (3-
ethylbenzthiazoline-6-sulfonate) were added and incubated for 30 min, and 405 nm emission was 
read within 30 min. PBS containing 3% BSA alone was used as a negative control and anti-CD4 
and anti-CD8 antibodies were used as positive controls. 
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The 40th percentile (50 ng/mL) of anti-CD4 IgG was used to define the cutoff for high and low 
levels of the IgG. Therefore, patients with plasma anti-CD4 IgG level above 50 mg/mL was 
defined as the high anti-CD4 IgG group; and patients with plasma anti-CD4 IgG level equal or 
below 50 ng/mL was defined as the low anti-CD4 IgG group. 
 
Plasma levels of LPS, soluble CD14 (sCD14), LPS binding protein (LBP) 
Plasma samples were collected into tubes containing EDTA and stored at −80°C until they were 
thawed once. The method was descripted from our previous studies 41-43. Briefly, the plasma 
samples were diluted to 10% with endotoxin-free water, and LPS was quantified using a 
commercially available limulus amebocyte assay kit (Lonza Inc., Allendale, NJ) according to the 
manufacturer's protocol. sCD14 and LBP were quantified using kits from R&D (Minneapolis, 
MN) and Hycult Biotech (Plymouth Meeting, PA) respectively following manufacturers’ 
protocols. 
 
Quantitative polymerase chain reaction (PCR) for measurement of bacterial 16S rDNA 
DNA was extracted from 400µL endotoxin free water and 400 µL plasma using QIAamp UCP 
pathogen Mini kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. The 
method was descripted from our previous studies 31,41. Briefly, a 20 µL amplification reaction 
consisted of 10 µL of 2x Perfecta qPCR ToughMix (Quanta, Gaithersburg, MD), 0.3 µmol/L 
forward and reverse primers, 0.175 µmol/L probe (338P: 5'-FAM-
GCTGCCTCCCGTAGGAGT-BHQ1− 3'), and 5 µL of the template plasma DNA. Degenerate 
forward (8F: 5'-AGTTTGATCCTGGCTCAG-3') and reverse (515R: 5'-
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GWATTACCGCGGCKGCTG-3') primers were used to amplify DNA templates encoding 16S 
rRNA. The DNA was amplified in duplicate, and mean values were calculated by subtracting 
values in the water control. A standard curve was created from serial dilutions of plasmid DNA 
containing known copy numbers of the template. The reaction conditions for amplification of 
DNA were 95°C for 5 min, followed by 40 cycles at 95°C for 15 s and at 60°C for 1 min 41.  
 
Plasma microbial DNA extraction, sequencing and data process 
Microbial DNA extraction was described above in 16S rDNA assay.  The 16S rRNA gene V4 
variable region PCR primers 515/806 with barcode on the forward primer were used in a 30 
cycle PCR (5 cycle used on PCR products) using the HotStarTaq Plus Master Mix Kit (Qiagen, 
USA) under the following conditions: 94°C for 3 minutes, followed by 28 cycles of 94°C for 30 
seconds, 53°C for 40 seconds and 72°C for 1 minute, after which a final elongation step at 72°C 
for 5 minutes was performed.  After amplification, PCR products were checked in 2% agarose 
gel to determine the success of amplification and the relative intensity of bands. Multiple 
samples were pooled together (e.g., 100 samples) in equal proportions based on their molecular 
weight and DNA concentrations. Pooled samples were purified using calibrated Ampure XP 
beads. Then the pooled and purified PCR product was used to prepare the DNA library by 
following Illumina TruSeq DNA library preparation protocol. Sequencing was performed at MR 




The Q25 sequence data derived from the sequencing process was processed using a proprietary 
analysis pipeline (www.mrdnalab.com, MR DNA, Shallowater, TX). Sequences were depleted of 
barcodes and primers, then short sequences < 200bp and sequences with ambiguous base calls, 
and sequences with homopolymer runs exceeding 6bp were removed. Next, sequences were 
denoised and operational taxonomic units (OTUs) were defined clustering at 3% divergence 
(97% similarity) followed by removal of singleton sequences and chimeras 44-48. Final OTUs 
were taxonomically classified using BLASTn against a curated database derived from 
GreenGenes, RDPII and NCBI 49. The data has been summarized at each taxonomic level by 
both raw counts and relative abundances. For each plasma sample and water control, absolute 
and relative abundance in OTU tables were generated. To control for contamination, two water 
samples were used as negative controls for DNA extraction. ß-diversity is different from the 
samples of patients, healthy and water controls (Supplemental figure 1). In the data analysis, we 
used both method of subtracting the mean abundance of the OTUs and removing any OTUs that 
are present in the water control. The PERMANOVA variability from both methods are the same. 
The results in this paper were presented based on method of removing mean absolute abundance 
of OTUs. See supplemental table 1 for the raw data of the read counts and relative abundance 
from each sample including water controls. 
 
Statistical Analysis 
In the pre-specified hypothesis, we were interested in the comparisons of HIV+ high anti-CD4 
antibody group versus HIV+ low anti-CD4 antibody group or healthy controls; therefore, P 
values from comparing HIV+ high anti-CD4 antibody group to each control group were not 
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adjusted for multiple comparisons 50. Non-parametric Mann-Whitney U tests were applied to the 
current study. 
 
For microbiome analysis, OTU tables and different levels of taxonomy tables derived from the 
sequencing process described above were imported to R (version 3.3.1) for statistical analysis 51. 
The mean values of two negative controls were subtracted from each sample’s OTU to control 
for the contamination. Simpson index of diversity was calculated using Vegan package 52 
measure α diversity of each sample. Spearman’s Correlation test were used to assess the 
association among Simpson diversity index, clinical and demographic characters and 
autoreactive antibody. Bray-Curtis and Jaccard dissimilarity were calculated using Vegan 
package to evaluate ß-diversity, the compositional dissimilarity among the microbial community. 
Jaccard dissimilarity measures the dissimilarity between samples based on the presence/absence 
of the data, whereas Bray-Curtis dissimilarity was calculated based on both presence/absence 
and abundance. The relationships between ß-diversity of the microbial community and 
autoreactive antibody titer were assessed using PERMANOVA in Vegan package. Analysis of 
indicator species (Indicspecis package) was used to assess the relationship between the 
occurrence/abundance of species at the genus level with different clinical characters. False 
discovery rate (FDR) correction was applied to control for multiple comparisons. 
 
Results 
A total of 34 participants completed the study, including 22 HIV patients and 12 healthy controls. 
Demographic characteristics of the participants are illustrated in Table 1.  
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Plasma anti-CD4 IgG level but not anti-CD8 IgG level was increased in aviremic ART-
treated HIV+ subjects compared to healthy controls 
Following our recent work, we investigated the mechanism of anti-CD4 autoantibody production 
in well-controlled ART-treated HIV infection. We first analyzed plasma levels of anti-CD4 IgG 
as well as anti-CD8 IgG in age-matched healthy controls and aviremic ART-treated HIV-
infected subjects. We found that the plasma level of autoreactive anti-CD8 IgG was similar in 
controls and HIV+ subjects, but the level of anti-CD4 IgG increased in the HIV+ subjects 
compared to controls (Figure 1A-1B), suggesting that B cell function is still abnormal even after 
long-term ART treatment and successful viral suppression. 
 
Plasma microbial translocation was elevated in HIV+ subjects with high plasma anti-CD4 
IgGs compared to healthy controls   
 
Next, to investigate the association of systemic microbial translocation and plasma anti-CD4 
IgGs level in HIV-infected subjects, we stratified patients to either high plasma autoantibody 
level or low plasma autoantibody level group. The cutoff value of 50 ng/mL plasma anti-CD4 
IgG was defined based on 40 up-percentile, and no healthy controls were above that value. 
Notably, both plasma LPS level and bacterial 16S rDNA level, markers of microbial 
translocation 41, tended to increase in HIV+ subjects with plasma anti-CD4 IgG below 50 ng/mL 
compared to healthy controls but have not achieved significant differences (Figure 1C-1D). 
Importantly, HIV+ subjects with high plasma level of anti-CD4 IgGs exhibited significantly 
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elevated plasma microbial translocation (Figure 2), suggesting that residual increased systemic 
microbial products may be associated with autoantibody production. In addition, we have 
evaluated the other two markers related to microbial translocation, sCD14 and LBP in plasma. 
Indeed, HIV+ subjects with high anti-CD4 IgGs had increased plasma sCD14 (Figure 1E) and 
LBP (Figure 1F) levels compared to the other two study groups. These results suggest that HIV+ 
subjects with high plasma anti-CD4 IgGs, but not HIV+ subjects with low plasma anti-CD4 
IgGs, had increased systemic microbial translocation compared to healthy controls.  
 
Distinct plasma microbial profiles in HIV+ subjects with high anti-CD4 IgGs compared to 
controls   
To investigate the difference of microbial translocation in healthy controls and HIV+ subjects, 
we performed and analysed plasma microbiome (Figure 2A-2E). The samples yielded a total of 
1,218,338 reads with an average of 34758.15 (±15380.71) reads per subject and 18280.5 
(±10127.89) reads for water control. A total of 2408 OTUs were found in samples of all 34 
subjects. On average, 400 (± 98) OTUs were found in each sample. In contrast, 439 OTUs 
(average 272 ± 76) were found in the water control, and the top phyla were Proteobacteria 
(79.3%), Firmicutes (12.5%), Deinococcus-Thermus (7.3%), Cuampbacteroa (0.7%) and 
Actinobacteria (0.2%). In the phylum levels among all samples, 57.4% were Proteobacteria, 
19.2% were Firmicutes, 10.5% were Actinobacteria, and 6.4% Bacteroidetes in plasma (Figure 
2A). A decreased ratio of Firmicutes/Bacteroidetes was reported on the fecal microbiome in 
autoantibody-derived autoimmune disease such as systemic lupus erythematosus (SLE) 53,54. In 
this study, the ratios of Firmicutes/Bacteroidetes were 0.58±0.45 in healthy controls, 0.37±0.38 
in the low anti-CD4 IgG HIV+ subjects, and 0.32±0.30 in the high anti-CD4 IgG HIV+ subjects, 
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respectively, but did not achieve significant difference between any two groups (mean±SD, P > 
0.05).  At the class level, Gammaproteobateria, Betaproteobacteria, Bacilli and 
Alphaproteobacteria were predominant (80.3%) in the low anti-CD4 IgG group (Figure 2B). 
Notably, the plasma enrichment of Alphaproteobacteria class was significantly higher in the low 
anti-CD4 IgG patient group compared to the high anti-CD4 IgG patient group after controlling 
for FDR (t = 3.22, P < 0.05, Figure 2B). At the family level, Staphylococcaceae and 
Pseudomonadaceae were increased in the high anti-CD4 IgG patient group compared to the 
other two groups (Figure 2D). At the genus level, Alicycliphilus, Pseudomonas, and 
Staphylococcus had increased relative abundance in the high anti-CD4 IgG patient group 
compared to the low anti-CD4 IgG patient group. (Figure 2E). Although the microbial 
components were different from the phylum to genus levels in HIV+ subjects with high anti-
CD4 IgGs compared to the other two groups, these differences were not significant after 
controlling for FDR.  
 
Reduced plasma microbial diversity was associated with increased plasma anti-CD4 
antibodies in HIV-infected individuals 
Next, to investigate the difference of composition in plasma microbiome in the three study 
groups, we analysed microbial diversity including Simpson Diversity Index, Shannon index and 
species number observed. The Simpson and Shannon diversity indexes in the high anti-CD4 IgG 
HIV+ subject group were significantly lower compared to the low anti-CD4 IgG HIV+ subject 
group (P = 0.04 and P = 0.05 respectively, Figure 3A and 3B). The numbers of species were 
365.8±99.6 in healthy controls, 373.5±91.2 in the low anti-CD4 IgG HIV+ subjects, and 
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362.1±85.7 in the high anti-CD4 IgG HIV+ subjects, respectively (mean±SD, P > 0.05). There 
was an inverse correlation between plasma anti-CD4 IgG level and the Simpson diversity index 
in HIV+ subjects but not in healthy controls (Figure 3C and 3D). Moreover, ß-diversity, the 
compositional dissimilarity among the microbial community was assessed using nonmetric 
dimensional scaling with both Bray-Curtis Coefficient and Jaccard Index, and revealed 
significant clusters between HIV-infected subjects with plasma anti-CD4 IgG level > 50 ng/mL 
and their counterparts (Figure 4). Nonetheless, anti-CD4 IgG level explained 6.8% of the 
variation of Bray-Curtis coefficient among HIV-infected individuals after controlling for plasma 
LPS level, duration of the ART treatment and CD4 counts (PERMANOVA, n = 22, P < 0.05); 
PERANOVA test of anti-CD4 IgG level on Jaccard Index yielded a similar result. Indicator 
species analysis showed that patients who had a higher level of anti-CD4 IgG (> 50 ng/mL) had 
significantly higher levels of Alicycliphilus (P < 0.05) and Hylemonella (P < 0.05). However, the 




Increased levels of autoreactive antibodies or autoimmune diseases have been shown in HIV/SIV 
infection 55-62. ART treatment reduces B cell hyperactivation 63. Our recent study shows that anti-
CD4 autoantibodies purified from plasma of immunologic non-responders (undetectable plasma 
viral load, ART-treated, and CD4+ T cell counts < 350 cells/µL) mediated CD4+ T cell death 
through antibody-dependent NK cell cytotoxicity, suggesting that anti-CD4 IgG plays a role in 
poor CD4+ T cell recovery under viral suppressive ART treatment 22. In the current study, we 
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found that both quantity and quality of plasma microbial products in ART-treated HIV-infected 
subjects was associated with anti-CD4 autoantibodies. 
 
Microbial TLR and its agonists play a role in autoantibody production and autoimmune diseases 
64,65. Our previous study showed that plasma level of TLR4 ligand LPS was associated with 
inflammation and B cell activation in HIV disease 43. Although ART treatment greatly reduces 
cell apoptosis and activation and thus limits autoantibody production 43,66-69, we found that anti-
CD4 specific antibody is a key exception (Figure. 1A). Moreover, altered B cell receptor (BCR) 
and TLR signals (e.g., MyD88) may promote autoreactive B cell selection 70. Indeed, HIV+ 
subjects had elevated levels of microbial translocation (Figure. 1C-1D) and cycling B cells 31 
compared to healthy controls, implying that bacterial products (e.g., LPS) may play a role in 
activating B cells. Nonetheless, how microenvironmental and inflammatory factors drive the 
breakdown of B cell tolerance, especially in humans, is not fully understood. Notably, 
autoimmune diseases in HIV are often observed after ART 55,71,72, implying that pathologic 
autoantibodies are developed post the ART treatment.  
 
Interestingly, a diverse bacterial DNAs were found in the plasma of healthy controls (Figure 2). 
These findings are consistent with the study from Païssé S 73. Low levels of microbial 
translocation occur in healthy individuals but increase when there is a GI barrier disruption. On 
the other hand, dysbiosis of gut microbiome community may result in mucosal immune 
dysfunction and intestinal mucosal barrier damage, which allows gut microbial translocation to 
the bloodstream 74,75 76-78. Increased “leakiness” of microbial products (e.g., LPS) from the 
intestinal barrier further may cause systemic immune cell activation and drives immune 
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perturbations 32. Intestingly, we observed a trend decrease in the Firmicutes/Bacteroidetes ratio 
in HIV+ subjects with high anti-CD4 IgG level compared to the other two groups, which is 
consistent with prior reports on the fecal microbiome in autoimmune disease such as systemic 
lupus erythematosus (SLE) 53,54. 
 
 
Most microbiome studies used stool, saliva, or cervical-vaginal lavage fluid samples, very rare 
study was done on plasma microbiome due to highly technical demands 32,79-81. A recent study 
reported that HIV-infected patients had different fecal microbial community composition 
compared to healthy controls 32. Fecal microbiome from HIV-infected patients was enriched in 
Enterobacteriales, Erysipelotrichaceae, Proteobacteria, Enterobacteriaceae, 
Gammaproteobacteria, Erysipelotrichi, Barnesiella, and Erysipelotrichales, but was depleted in 
Rikenellaceae and Alistipes, relative to healthy controls 32. Another study showed that HIV-
infected patients with low peripheral CD4+ T cell counts exhibited reduced enteric bacterial 
diversity, which is consistent with our findings 79. Both studies indicate that enrichment of 
Enterobacteriaceae was associated with systemic inflammation 32,79. Consistently, plasma 
enrichment of Proteobacteria, Gammaproteobacteria and Betaproteobacteria was also observed 
in HIV+ individuals compared to healthy controls in the current study, but the difference did not 
achieve statistical significance (Figure 2). However, we did not observe enrichment in other 
bacteria products reported in the fecal microbiome study besides Proteobacteria, 
Gammaproteobacteria and Betaproteobacteria in plasma from HIV+ individuals relative to 
healthy controls 32. Nonetheless, it is important to investigate microbiome simultaneously in 
plasma and mucosal sites in HIV in the future. 
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TLR4 signaling was increased with transgenic mice for a TLR chaperone molecule (gp96), 
which resulted in a lupus-like autoimmune glomerulonephritis (26). Flares of autoimmune 
diseases have been observed with infection 82 in humans and also is a inducer of autoimmunity in 
mice. Decreased anti-dsDNA antibodies were observed in TLR2 and TLR4 knockout C57BL/6 
(lpr/lpr) mice; and autoantibodies were induced by LPS stimulation through TLR4-dependent 
cell signaling pathway in lupus-prone mice 83,84. Therefore, increased bacterial product 
translocation may play a key role to induce autoantibodies in HIV. However, the association of 
plasma bacterial products (e.g., LPS) and anti-CD4 IgG level we observed in the current study 
does not prove causality. Next, we will give HIV-infected humanized animal models with 
specific bacterial products (e.g., LPS) found in plasma of the high HIV+ subjects to evaluate 
anti-CD4 autoantibody production. The other possibility of this association can be high anti-CD4 
autoantibody-mediated immunodeficiency (poor CD4+ T cell recovery 22) and increased 
inflammation favor particular bacterial survival. Furthermore, plasma soluble CD4 level was 
similar among the three study groups 22, suggesting that increased anti-CD4 IgG in some patients 
may not result from increased antigens in plasma. However, we do not know whether the level of 
CD4 antigen and HIV proteins (e.g., gp120 85) with CD4 binding capacity is increased in lymph 
nodes, raising the question that increased anti-CD4 IgG may be due to increased antigens in the 
patients with high anti-CD4 IgG level. 
 
Women in general have higher humoral and cellular immune responses relative to men, as well 
as higher prevalence of autoimmune diseases  86. Mechanisms accounting for sex differences in 
autoimmune diseases include sex-induced breaks in tolerance and increases in peripheral cell 
activity, such as TLR responsiveness, T regulatory cells, environmental and genetic factors 87-90. 
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Consistently, we found that there were more women in the high HIV+ anti-CD4 autoantibody 
group compared to the low HIV+ anti-CD4 autoantibody group (Table 1). Whether anti-CD4 
autoantibody induced by female sex hormones or sex hormone-mediated immune responses is 
worth further investigation. 
 
This is the first study to date to report plasma microbiome and microbial products (e.g., LPS) in 
relation to autoantibodies in HIV patients. One of its limitations remains a small sample size. 
Due to the small sample size and large amount of microbial species observed in the plasma, most 
significant differences of microbiome among the study groups were not demonstrable after FDR 
correction. Another limitation is that other factors that may influence gut microbiota composition 
and bacterial translocation, such as diet, usage of probiotics and antibiotics, and the comorbidity 
of the patients were not controlled in the study. Therefore, the interpretation and generalization 
of findings may be limited. Future studies with large and diverse sample sizes are needed to lead 
a greater understanding of the concept of microbial translocation and auto-immune responses. In 
addition, the contributing factors for microbiome including sex should be considered.   
 
In summary, we found that elevated plasma anti-CD4 IgG in HIV-infected subjects was 
associated with the magnitude of systemic microbial translocation and systemic microbiome. At 
the class level, Gammaproteobateria, Betaproteobacteria, Bacilli and Alphaproteobacteria were 
predominant in the low anti-CD4 IgG group. At the genus level, Alicycliphilus, and Hylemonella 
had elevated relative abundance in the high anti-CD4 IgG patient group compared to the low 
anti-CD4 IgG patient group. These results suggest that systemic microbial translocation and 
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microbiome may play a role in anti-CD4 autoantibody production in HIV infection. However, 
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Figure 1. Plasma level of anti-CD4 IgG and its association with microbial translocation in HIV+ 
subjects. sCD4 and sCD8 proteins were used to detect plasma anti-CD4 IgGs (A) and anti-CD8 
IgGs (B) by ELISA. Plasma levels of LPS were detected by limulus amebocyte assay (C), 
bacterial 16S rDNA were detected by qPCR (D), sCD14 (E) and LBP (F) by ELISA in healthy 
controls and HIV+ subjects with plasma anti-CD4 IgG > 50 ng/mL and ≤ 50 ng/mL. Non-
parametric Mann-Whitney tests. 
 
Figure 2. Circulating microbiome relative abundance analysis in healthy controls and HIV+ 
subjects. Microbial DNA was extracted from plasma and V4 variable region of bacterial 16S 
rDNA gene was amplified. The relative abundance of phylum (A), class (B), order (C), family 
(D), and genus (E) level bacteria (> 1%) were shown in plasma from healthy controls, HIV+ 
subjects with plasma anti-CD4 IgG level ≤ 50 ng/mL and HIV+ subjects with anti-CD4 IgG > 50 
ng/mL. The plasma enrichment of Alphaproteobacteria class was significantly higher in the low 
anti-CD4 IgG patient group compared to the high anti-CD4 IgG patient group after controlling 
for FDR. 
 
Figure 3. Reduced diversity was associated with increased plasma level of anti-CD4 
autoantibody in HIV+ subjects. Box and whiskers plots of the Simpson (A) and Shannon (B) 
diversity indexes of plasma samples from HIV+ subjects with anti-CD4 IgG levels ≤ 50 ng/mL, > 
50 ng/mL and health controls. The top and bottom boundaries of each box indicate the 3rd and 1st 
quartile values, respectively. The central horizontal line represents the median values. The dot 
	 62	
represents Simpson and Shannon diversity index of each sample. Non-parametric Mann-Whitney 
U tests. Correlations between the Simpson diversity index and plasma anti-CD4 IgG levels in 
healthy controls (C) and HIV+ subjects (D). Spearman correlation tests.  
 
Figure 4. Nonmetric multidimensional scaling ordination (NMDS) plot of the OTUs with fitted 
vectors of clinical variables (A), and based on the abundance of bacterial phyla (B). Dots with 
different colors represent data from each plasma sample in HIV+ subjects with anti-IgG level ≤ 
50 ng/mL (red) and HIV+ subjects with anti-CD4 IgG > 50 ng/mL (green). Ellipses denote the 
standard deviation of weighted average NDMS score of anti-IgG level ≤ 50 ng/mL group (red) 
and anti-CD4 IgG > 50 ng/mL group (green). Community differences were verified by 
PERMONOVA test (Adonis, P < 0.05). Arrows represent the direction and magnitude of 















low HIV+/!CD4high P1 P2   P3  
Number 12 13 9    
Age 43.5 (33.5-56) 43 (26-46.5) 47 (36-56.5) 0.25 0.77 0.21 
Gender (Male/%) 3 (25%) 11 (84.6%) 3 (33.3%) 0.005 >0.99 0.04 
Race (AA/%) 7 (44%) 8 (57%) 7 (58%) 0.72 0.7 0.52 
Nadir CD4 count (cells/"L) 361 (226-490) 229 (124-426)  0.19 
Duration of ART (yr)  4 (3.5-6.5) 6 (4-6)   0.82 
CD4 count (cells/"L) 828 (523-1043) 634 (514-744) 450 (321-677) 0.50 0.07 0.07 
%ki67+ CD4 1.0 (0.7-1.6) 2.8 (1.9-3.8) 2.5 (1.7-3.9) < 0.0001 0.001 0.73 
%annexin V+ CD4 19 (13.5-37.7) 29.4 (27.1-43) 26.9 (15.7-32) 0.14 0.60 0.18 
B cell count (cells/"L) 219 (112-235) 239 (132-314) 185 (130-245) 0.29 0.65 0.37 
%ki67+ B cells 0.9 (0.7-1.1) 1.5 (0.9-2.0) 1.3 (0.9-2.7) 0.03 0.03 0.84 
%annexin V+ B cells 9 (5.5-18) 19.4 (12.6-27.8) 17.6 (13.3-33) 0.007 0.04 0.86 
Plasma soluble CD4 
(ng/mL) 2.1 (1.2-4.9) 1.7 (0-2.7) 1.8 (0.3-2.7) 0.37 0.39 0.66 
Current ART regimen       
Multi-Class 
Combination  11 (84.6%) 4 (44.4%)   >0.99 
NRTIs  2 (15.4%) 3 (33.3%)   0.71 
PIs  3 (23%) 3 (33.3%)   >0.99 
Metabolic abnormities       
BMI  26.1 (23.3-29.7) 32.3 (24.9-38.3)   0.14 
Diabetes mellitus  1 (0.08%) 1 (0.11%)   >0.99 
Hypertension  4 (30.8%) 2 (22.2%)   0.67 
Abnormal lipid 
metabolism  5 (38.5%) 3 (33.3%)   0.67 
       P1: HIV- vs HIV+/!CD4low 
     P2: HIV- vs HIV+/!CD4high 
     P3: HIV+/!CD4high vs HIV+/!CD4low 
          
Non-parametric Mann-Whitney tests. 
Abnormal lipid metabolism: hyperlipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia 
Multi-Class Combination ART: Two different groups in a complete HIV drug regimen (e.g., Atripla (bictegravir + 
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Abstract 
Background: Preterm infants are at great risk for severe infections due to their immature 
immune system. However, the factors that influence the maturation of gut immune systems and 
their underlying mechanism remains unclear. Recent research suggests that pain/stress plays a 
role in immune activation and inflammatory process. Fecal calprotectin (FCP) levels have been 
proposed as a non-invasive biomarker measuring gut inflammation in both adults and neonates. 
Objective: The purpose of the study was to examine the relationship between cumulative 
pain/stress and gut FCP levels in preterm infants in the neonatal intensive care unit (NICU). 
Methods: The study used a longitudinal approach. Stable preterm infants were recruited 
in the NICU setting. Cumulative pain/stress was measured daily using a modified Neonatal 
Infant Stress Scale (NISS). Stool samples were collected and FCP levels were quantified using 
the enzyme-linked immunosorbent assay twice weekly. Both NISS scores and FCP levels were 
measured in preterm infants during the first four weeks of their NICU stay. Linear mixed effect 
model was used to examine the association among cumulative pain/stress, demographic and 
clinical characteristics (i.e., feeding type, antibiotics use, gestational age), and FCP levels. 
Results: Thirty-one preterm infants were included in the study who were primarily White 
(77.4%), non-Hispanic (77.4 %), female (61.3 %), and born at 30.9 ± 1.5 weeks gestational age 
with premature rupture of membranes (32.3%) and by cesarean-section (77.4%). Nineteen 
infants (61.2%) had antibiotics during the first 48 to 72 hours post-delivery. These preterm 
infants experienced an average of 23.4 (± 6.3) acute painful procedures and 14.2 (± 20.3) hours 
of chronic painful procedures during the first four weeks of life in the NICUs. These infants’ 
FCP levels varied largely with a mean of 267.6 ± 262.7 (µg/g) during the first four weeks of life. 
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Elevated FCP concentration was positively associated with chronic (prolonged) pain/stress (p < 
0.01), antibiotics use (p < 0.01), and premature rupture of membranes (p < 0.05).  
Discussion: Fecal calprotectin level was elevated in preterm infants with wide inter- and 
intra-individual variation. Cumulative pain/stress influences the FCP concentration in preterm 
infants during the first four weeks of life. These findings indicate that cumulative pain/stress is 
positively associated with the gut inflammatory process.  
Key Words: Fecal calprotectin, gut inflammation, preterm infant, pain, stress, ELISA 
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The Impact of Cumulative Pain/Stress on Fecal Calprotectin Levels in Preterm Infants 
Approximately 10% of infants are born prematurely every year in the U.S (Hamilton, 
Martin, Osterman, Curtin, & Matthews, 2015). Preterm infants are vulnerable to morbidity and 
mortality related to severe infections (i.e., neonatal sepsis, necrotizing enterocolitis). The 
mortality rate of preterm infants with systemic infection is up to 40 percent in the United States 
(McGuire, Clerihew, & Fowlie, 2004). The increased risks for infection in preterm infants is 
profoundly due to the developmental immaturity of the gut, which characterized by immature 
(leaky) mucosal and epithelial barriers, increased intestinal permeability as well as an immature 
immune system (Sharma, Jen, Butler, & Lavoie, 2012). 
The factors that influence the maturation of gut immune systems are complex and 
multifactorial. Preterm infants are exposed to numerous stressors (medical, psychosocial and 
environmental) in the Neonatal Intensive Care Unit (NICU). Evidence shows that increased 
exposure to stressors in early life stimulates pro-inflammatory compounds and leads to long-term 
immune cell activation (Grunau, 2013). However, the underlying mechanism of early life stress 
altering immune functions remains unclear. An expanding area of research supports that the 
function of the brain-gut axis plays a key role in the regulation of stress and early programming 
of the neuro-immune system (Cong, Henderson, Graf, & McGrath, 2015; Mayer, Tillisch, & 
Gupta, 2015). Physical and emotional stress, including painful procedures and maternal 
separation, may result in altered epithelial barrier integrity, increased intestinal permeability 
(leaky gut), up-regulation pro-inflammatory mediators, and activation of immune and somatic 
cells through pathogen-associated receptors that trigger inflammation (Ghaisas, Maher, & 
Kanthasamy, 2016; M. W. Groer, Gregory, Louis-Jacques, Thibeau, & Walker, 2015; M. W. 
Groer et al., 2014; Moloney, Desbonnet, Clarke, Dinan, & Cryan, 2014). 
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Fecal calprotectin (FCP) is a non-invasive biomarker that measures inflammation in the 
GI tract (M. Groer, Ashmeade, Louis-Jacques, Beckstead, & Ji, 2016; Ho et al., 2015; 
Kawashima et al., 2016; van Rheenen, Van de Vijver, & Fidler, 2010; Walsham & Sherwood, 
2016). Fecal calprotectin is a calcium-binding protein that is primarily excreted by granulocytes, 
and also expressed by monocytes/macrophages and epithelial cells. FCP accounts for about 60% 
of the cytosolic proteins in neutrophil granulocytes (Dale, Brandtzaeg, Fagerhol, & Scott, 1985) 
and is involved in intracellular signal transduction, neutrophil defense, immunoglobulin 
production and regulating inflammatory responses (Roseth, Fagerhol, Aadland, & Schjonsby, 
1992). Elevated FCP has been shown to be related to the migration of neutrophil granulocytes 
into the intestinal mucosa toward the lumen, which usually occurs during intestinal inflammation 
(Bjerke, Halstensen, Jahnsen, Pulford, & Brandtzaeg, 1993; Roseth, Schmidt, & Fagerhol, 1999). 
Moreover, FCP has been successfully used in detecting inflammation among patients with 
inflammatory bowel disease (IBD) (Kawashima et al., 2016; van Rheenen et al., 2010; Walsham 
& Sherwood, 2016) and necrotizing enterocolitis patients (Albanna, Ahmed, & Awad, 2014; 
Aydemir et al., 2012; Benitez & Garcia-Sanchez, 2015; Yoon et al., 2014). Calprotectin has been 
proposed as a biomarker predicting IBD relapse, with a sensitivity of 90% and a specificity of 83% 
(Tibble, Sigthorsson, Bridger, Fagerhol, & Bjarnason, 2000). As an extremely stable protein, 
FCP has become a newer diagnostic tool to detect intestinal inflammation. 
The purpose of the study is threefold: 1). To describe the FCP levels in preterm infants 
during the first four weeks of life; 2). To examine the association between cumulative stress in 
early life and FCP levels among preterm infants; 3). To explore the contributing factors that are 
associated with FCP levels.  
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Methods 
Study Design and Participants 
This study used a secondary analysis approach. The original data were collected by Cong 
et al., in relation to increasing understanding of the gut/brain axis and the microbiome 
(#1K23NR014674). From October 2013 through June 2017, a total of 93 infants have been 
recruited from the Connecticut Children’s Medical Center (CCMC) NICUs at Hartford and 
Farmington, CT.  
The original study used a prospective longitudinal design to examine preterm infants’ gut 
microbiome patterns over the first four weeks of NICU stay. Infants were followed in the NICU 
for 3-4 weeks after birth and information on cumulative pain/stress, medication use and feeding 
types were collected daily during the study period. Stool samples were also collect daily from 
birth till 28 days of postnatal age.  A neurodevelopment assessment was performed at an average 
of 38 weeks of corrected gestational age to examine long-term outcomes. The demographic 
characteristics of the infants of the original study included healthy infants born between 26–32 
weeks gestational age, male (52%), White (73%), non-Hispanic (71%), and Cesarean-section 
births (67%) (Cong, Judge, et al., 2017). 
Setting and Sampling 
Infants from the original study who meet the eligibility criteria were randomly selected 
for this secondary analysis. Inclusion criteria: Infants who were 26–32 weeks gestational age at 
birth, aged 0–3 days old and cared for in an incubator. The infant's mother and father had to be ≥ 
18 years old to give consent. Exclusion criteria: Infants who had: 1) known congenital 
anomalies; 2) severe periventricular/intraventricular hemorrhage (≥ Grade III); 3) undergone 
minor or major surgery including procedures such as inguinal hernia repair, laparotomy, 
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thoracotomy, diaphragmatic hernia repair, or intestinal resection; and 4) history of illicit drug 
exposure during the current pregnancy. We randomly select 31 infants from the original study 
who had complete daily pain/stressor data and also had at least one stool sample per week for the 
first four weeks. 
Outcome Measures and Data Collection  
Demographic data and health characteristics. Demographic information including 
gestational age at birth, birth weight, sex, mode of delivery, the timing of rupture of membranes 
was extracted from the medical record.  The severity of illness soon after birth was measured by 
the Score for Neonatal Acute Physiology–Perinatal Extension II (SNPPEII) (Richardson, 
Corcoran, Escobar, & Lee, 2001). Information on postnatal antibiotics administration including 
generic names and duration of antibiotics use (day) were also collected. 
Cumulative Pain/stress. A modified version of the Neonatal Infant Stressor Scale (NISS) 
(Newnham, Inder, & Milgrom, 2009) was used to assess daily cumulative pain and stress (Cong, 
Wu, et al., 2017). The modified NISS instrument consists of 70 acute and chronic 
painful/stressful procedures and events that are commonly experienced by neonates in the NICU 
including daily care, feeding, imaging, blood draw, peripheral venous access, central venous 
access, respiratory care, surgeries and major procedures, and infection. Each procedure/event is 
assigned to a pain severity level from 1 to 5 (1= not painful/stressful; 2 = a little; 3 = moderate; 4 
= very; and 5 = extremely painful/stressful). Acute stress scores are compiled by summing up the 
weighted frequency of each acute event, whereas chronic stress scores are compiled by summing 
up the weighted duration of each chronic event. Cumulative pain and stress composite scores 
were calculated daily based on daily pain/stressor data for the first 4 weeks of life in preterm 
infants.  
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Fecal Calprotectin Assay. Daily stool samples from preterm infants were collected by 
research nurses in the original study using sterile, disposable spatulas during diaper changes and 
then placed into a sterile specimen container. Samples were immediately frozen upon collection 
at -80°C, then transferred to the lab and stored at -80°C until processing. The stool samples on 
the third and seventh day of each week from each infant were selected for the FCP assay and 
analysis.  A hundred milligram stool from each stool sample was aliquoted to a 15 ml falcon tube 
for FCP ELISA assay using the PhiCal kit (Calprest®, Eurospital S.p.A, Trieste, Italy) according 
to the manufacturer’s instructions. All the samples and standard controls from the kits were 
tested in duplicate. The inter-assay and intra-assay coefficients of variation were calculated for 
quality control. The mean coefficient of variation was less than 3% (Rouge et al., 2010). The 
reported sensitivity and specificity of the PhiCal test in pediatric population were 93.2% and 86.6% 
respectively (Radillo, Pascolo, Martelossi, Dal Bo, & Ventura, 2016).  
Feeding Type. Infant daily feeding information including the frequency of infant fed by 
mother’s milk (MOM), human donor’s milk (HDM), and formula over the first four weeks of life 
was also extracted from the medical record. The frequency and percentage of each feeding type 
(MOM, HDM, or formula) for each infant were calculated daily and over each week. We also 
categorized study infants into MOM group and non-MOM groups based on >70% of the total 
frequency of feeding of the first four weeks. For example, an infant fed MOM for more than 70% 
of the total feeding time was assigned to the MOM group. 
Statistical Analysis 
Data were analyzed using the R (version 3.2.4) software packages. Descriptive methods 
were used to generate summary statistics of study variables.  Effects of acute and chronic 
pain/stress on FCP levels were assessed via a general linear mixed-effects regression modeling 
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using the lme4 package in R (Bates, Mächler, Bolker, & Walker, 2015). Missing data were 
deleted from the analysis. We obtained p values for regression coefficients using the car package 
(Fox & Weisberg, 2011). Variance inflation factors were performed using R to evaluate the 
severity of multicollinearity among the factors of mixed effect model. GGplot2 package in R was 




Thirty-one preterm infants were randomly selected for inclusion in this study from the 
larger study sample. The demographic characteristics were indicated in Table 1. A total of 194 
stool samples were aliquoted for FCP analysis with an average of 5.5 (± 1.4) stool samples from 
each infant over the 4-weeks period after birth. The earliest stool sample that was obtained for 
FCP analysis was on the postnatal day 3. 
Fecal Calprotectin concentration 
The mean value and standard deviation (SD) of FCP levels were 267.6 ± 262.7µg/g, with 
a wide range of 23.1 µg/g to 1320.2 µg/g. The inter- and intra-individual coefficients of variation 
were 81.4% and 76.86% respectively. The FCP levels decreased significantly from week 1 
(mean ± SD: 309.2 ± 287.2 µg/g) to week 2 (mean ± SD: 160.0 ± 201.3 µg/g) and then increase 
on week 3 (mean ± SD: 272.6 ± 260.1 µg/g) and week 4 (mean ± SD: 351.7 ± 290.6 µg/g) 
(Figure 1). One-way ANOVA of mean FCP levels significantly differed among 4 weeks 
(F(3,190) = 5.609, p = 0.001). Tukey's honest significant difference (HSD) post hoc test 
indicated that mean FCP levels were significantly different between week1 and week 2, and 
week 2 and week 4. 
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Cumulative pain/stress and relations with FCP values 
Preterm infants experienced an average of 23.4 (± 6.3) acute painful procedures daily and 
14.2 (± 20.3) hours of daily chronic painful procedures during the first four weeks of life in the 
NICU. Figure 2 shows the average unweighted amount of weekly acute (2A) and chronic (2B) 
pain/stressors during the first, second, third, and fourth week. Linear regression model showed a 
decreased trend in both the daily acute NISS scores (F (1,182) = 26.06, p < 0.001, R2 = 0.03), and 
daily chronic NISS scores (F (1,182) = 49.28, p < 0.001, R2 = 0.06) over the first four weeks of 
infant life in the NICU. In addition, both acute pain/stress (F (4, 182) = 6.059, p < 0.05) and 
chronic pain/stress (F(4, 182) = 6.571, p < 0.05) were positively associated with the FCP level 
after controlling post-natal weeks (Figure 3). 
Feeding types and relations with FCP values 
The initial enteral feedings were introduced between postnatal Day 1 to Day 6 (Mean = 
2.8, SD = 1.3). The feeding regimens for preterm infants were mixed with mother’s milk (MOM), 
human donor milk (HDM) and formula, except two infants who were fed exclusively with 
formula over the 4-week period. The overall percentage of feeding type for each infant during 
the first four weeks of life included 50.9% (± 29.0) of MOM, 25.4% (± 26.4) of HDM, and 23.8% 
(± 28.3) of formula. Nothing by mouth (NPO) status during the first four weeks of life ranged 
from 0 to 5 days (M=1.4, SD = 1.3). Infants with a higher percentage of MOM (F(4,168) = 6.8, p 
= 0.057 R2 = 0.12) and formula (F(4,168)=0.04 , p = 0.32, R2 = 0.10) tended to have an increased 
FCP level across time (Figure 4). In contrast, infants with a higher percentage of HDM (F(4,168)  
= 9.6, p < 0.001, R2=0.17) tended to have a lower FCP level over the four week period. 
Antibiotics use and relations with FCP values 
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Nineteen infants had antibiotics (Ampicillin and Gentamicin) during the first 48 to 72 
hours post-delivery, among those three infants had antibiotics for 10 days or above. There was 
no difference in the FCP level in infants who used antibiotics compared to infants without 
antibiotics use during the first three weeks (p > 0.05). However, the FCP level became 
significantly higher in infants who used antibiotics (433.4 ± 302.3 µg/g) during week 4 
compared to infants without antibiotics use (147.4 ± 100.7 µg/g) (t (39.3) = -4.58, p < 0.001) 
(Figure 5).   
Mixed-effects model 
To determine the effect of chronic pain/stress and other contributing factors to the FCP 
level, a general linear mixed effects model was conducted with FCP concentration as an outcome 
measure and pain/stress, feeding types, antibiotics use and demographic variables as the predict 
factors. The log transformation was applied to the FCP level to obtain a normal distribution. The 
analysis of the mixed effects model showed that an increased FCP level was associated with 
higher daily chronic pain/stress (p < 0.01), increased percentage of HDM intake (p < 0.01), 
premature rupture of membranes at birth (p < 0.01) and postnatal antibiotic therapy (p < 0.05). 
Factors including gestational age at birth, sex and mode of delivery were not significant (Table 
2). No evidence of multicollinearity was found given that all the variance inflation factors (VIF) 
were ≤ 5. A separate mixed effects model of acute pain/stress and FCP level shows similar 
results on the contributing factors described above, including feeding type, premature rupture of 
membranes at birth, postnatal antibiotic therapy, gestational age at birth, sex and mode of 
delivery, however, the effect of acute pain/stress disappeared (p = 0.064). 
 
 
PAIN/STRESS AND GUT INFLAMMATION IN PRETERM INFANTS 
 82 
Discussion 
The current study showed that FCP levels of preterm infants were elevated compared to a 
healthy standard. Previous studies also reported that FCP levels were higher in preterm infants 
compared to full-term cohorts (Kapel et al., 2010; Rouge et al., 2010). High inter-individual and 
intra-individual coefficients of variability were also observed in this study. Prior to proceeding 
with further data analysis and interpretation, technique and procedures of FCP assay were 
reviewed to account for any technical errors of measurement. All the samples and standard 
controls were tested in duplicate with low inter-assay and intra-assay coefficient of variation; 
both were lower than 10%, thus eliminating the error from the ELISA assay. Another concern 
arises with the stool collection technique, where water is absorbed into the diaper which leads to 
increased FCP level-up to 30% (Olafsdottir, Aksnes, Fluge, & Berstad, 2002). However, the 
variation observed in our study far exceed the variation caused by water absorption. In addition, 
based on the protocol of the study site, the diaper was changed every two hours. Once the sample 
was collected from the diaper, it was immediately transferred to a -80ºC freezer until processing. 
It is unlikely that FCP degraded during the data collection procedure. Therefore, we concluded 
that our data reflected true high concentration and variability of FCP in preterm infants. Our 
study findings were consistent with previous studies showing high FCP levels and large inter- 
and intra-individual variation in preterm infants (Josefsson, Bunn, & Domellof, 2007; Moussa, 
Khashana, Kamel, & Elsharqawy, 2016; Rouge et al., 2010).   
Fecal calprotectin, a cytoplasmic protein in neutrophil granulocytes is primarily found in 
the gut when the neutrophils migrate to the intestinal mucosa. Since calprotectin is not present in 
human’s milk (Olafsdottir et al., 2002), a high FCP level should be closely associated with the 
gut inflammation of preterm infants. One of the explanation is that preterm infants are more 
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likely to have immature intestinal mucosal and enhanced intestinal permeability (Weaver, Laker, 
& Nelson, 1984), which leads to increased trans-epithelial migration of neutrophils through 
intercellular junctions, and release calprotectin into the gut lumen (Berstad, Arslan, & Folvik, 
2000; Parkos, Colgan, Delp, Arnaout, & Madara, 1992). Our study found no correlation between 
the FCP level and gestational age before 34 weeks. It is possible that the level of FCP before 34 
weeks remains constantly high and does not vary significantly within the age window. Our 
findings add more specificity to the previous studies of the FCP level and gestational age 
(Campeotto et al., 2007; Josefsson et al., 2007; Li et al., 2014; Moussa et al., 2016; Yang, Smith, 
Goldberg, & Cotten, 2008). 
Meanwhile, controversial relationships between the FCP level and postnatal age have 
been reported previously (Josefsson et al., 2007; Li et al., 2014). We found that FCP levels 
decreased from the first to the second week, and then increased till the 4th week of life. This 
finding agrees with Josefsson’s (2007) study that the FCP level decreases during the first week 
postnatal and then increase to the 8th week. The elevated FCP level in meconium may not reflect 
the gut inflammation during the first week of life but due to the cumulative effect of FCP in 
meconium during pregnancy. 
The FCP level was significantly influenced by feeding regimen across time. Study infants 
who received a higher percentage of MOM feeding tended to have an increased FCP level across 
time. However, the increase was marginally significant, probably due to small sample sizes. In 
contrast, infants who were fed with a higher percentage of HDM or formula tended to have a 
lower FCP level. Several studies have investigated the relationship between feeding regimen and 
FCP and reported inconsistent findings. Our findings are in line with Groer’s study (2015) that 
exclusive MOM was found to be associated with an elevated FCP level in very low birth weight 
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infants during the first four weeks of life. Li (2014) and Asgarshirazi (2017) also reported the 
FCP level is higher in breastmilk-fed infants than non-breast fed ones. In contrast, Rouge (2010) 
found that the FCP level was significantly elevated in preterm infants who received exclusive or 
predominant formulas. Other authors found that feeding regimen was not significantly correlated 
with FCP (Campeotto et al., 2007; Josefsson et al., 2007; Yang et al., 2008).  
The increased FCP level may reflect protective mechanisms of MOM to the immature gut 
and represent the maturation of gut immunity. MOM contains microbiota and oligosaccharides, 
which are essential in the establishment of commensal bacteria, and promoting the maturation of 
preterm infants’ gut. In our previous study, we reported that MOM promotes the diversity of gut 
microbiome and early transition to adult-like microbial patterns in preterm infants compared to 
HDM and Formula (Cong, Judge, et al., 2017; Xu et al., 2017). Rouge’s (2010) study confirmed 
the effect of enteral bacterial in promoting FCP production, which could explain the postnatal 
changes of the FCP level in our population. In addition, MOM contains more than 109 leukocytes 
per liter for the first several months of lactation as well as other bioactive substances, such as 
pro-inflammatory cytokines, antibodies and other immune-stimulating factors (Asgarshirazi, 
Shariat, Nayeri, Dalili, & Abdollahi, 2017; Newburg & Walker, 2007; Wallace et al., 1997). 
Thus, the elevated level of FCP could also be a response to these immune factors present in 
MOM. Infant fed predominately with HDM showed a lower level of FCP concentration, which 
may due to the pasteurization removed commensal bacteria and inactivate immune components 
(Cong, Judge, et al., 2017; Ewaschuk, Unger, Harvey, O'Connor, & Field, 2011; Xu et al., 2017). 
Nineteen of the 31 infants received antibiotics postnatally, predominately Ampicillin and 
Gentamycin during the first 48 to 72 hours. There were only three infants in this study received 
extended antibiotics after the first week. Interestingly, we observed that FCP levels were similar 
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in infants with or without antibiotics use during the first three weeks, but then increased to a 
significantly higher level during the 4th week in infants who received postnatal antibiotics 
compared to infants who did not use antibiotics. However, Josefsson (2007) reported that FCP 
levels were significantly lower in infants with postnatal antibiotics use, specifically use of 
Cefotaxime and Meropenem compared to infants without antibiotic therapy. Since the types of 
antibiotics used in Josefsson’s study were different from the antibiotics in our study, therefore, 
results were not comparable. Rouge (2010) also reported a lower FCP level in infants with ante-
and post-natal antibiotic use, but the types of antibiotics were not reported in the study. Groer 
(2015) found no association between FCP and antibiotics use in a study that the majority of 
infants were given postnatal antibiotics, possibly due to the homogeneity of the antibiotics use. 
Antibiotics have been known to influence gut bacterial colonization and disrupt the microbial 
community. We speculate that prophylactic antibiotics use during the first 48-72 hours disrupt 
the infant’s gut microbiota colonization, particularly commensal bacteria during the first week of 
life. The imbalanced of gut community leads to a growth of certain groups of bacteria, which 
corresponded to an elevated FCP later during the first month. This speculation was also 
supported by findings in our study that infants with premature rupture of membranes have 
elevated FCP value. 
We found that both acute and chronic daily pain/stress are significantly positively 
correlated with the FCP level. However, when using a mixed-effect model and controlling for 
other variables, only the effect of chronic pain/stress on FCP remained significant. The effect of 
acute pain/stress on FCP became marginal significant, which may be due to small sample sizes. 
This study is the first to report the relationship of cumulative pain/stress experience and the FCP 
level in preterm infants. The findings supported our hypothesis that stress may alter epithelial 
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barrier integrity, increase intestinal permeability, leading to activation of the inflammatory 
process in the gut. Notably, the NISS scores were calculated daily based on the number of 
medical procedures the infants experienced in the NICUs. Therefore, FCP may also reflect the 
inflammation that was directly caused by these medical procedures, as well as the infants’ 
medical conditions.   
There are several limitations to this study. First, the mother’s information was not 
collected in this project. Mother’s antenatal conditions, such as medical complications, 
antibiotics use may influence the FCP level, especially during the first week. Common 
conditions like intra-uterine inflammation, causes premature immune activation and cytokine 
production and may account for the elevated FCP level in preterm infants.  Secondly, we did not 
include measures of other inflammatory markers such as cytokines (e.g., interleukin (IL)-1β, IL-
6, IL-8 and tumor necrosis factor (TNF)), c-reactive protein or cortisol in this study to better 
understand the sources and causes of the inflammation. Therefore, the effect of FCP as a marker 
in the prediction of infants’ health outcome is still inconclusive. Thirdly, gut microbiome data 
have not been included in this analysis to examine the correlations between microbiome, FCP 
and stress. However, our study results suggest that gut microbiome may be an essential pathway 
in modulating the effect of external stressors on the gut inflammatory process. Further studies 
need to be done exploring the mediation effect of gut microbiome patterns (i.e., diversity, 
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Conclusion 
This study demonstrates that preterm infants have high calprotectin concentrations with wide 
inter- and intra-individual variation during the first four weeks of life. The elevated FCP level 
was positively associated with MOM intakes, postnatal antibiotics use during the first 72 hours, 
pre-rupture of membranes and prolonged pain/stress during NICUs staying. Further work should 
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Table 1. Demographic and clinical characteristics of the preterm infants (N=31) 
Demographic n Percent (%) 
Gender Male 12 38.7 
Female 19 61.3 
Race White 24 77.4 
African American 6 19.4 
Not known 1 3.2 
Ethnicity Hispanic 7 22.6 
Non-Hispanic 24 77.4 
Delivery type Vaginal 7 22.6 
Cesarean section 24 77.4 
PROM Yes 10 32.3 
No 21 66.7 
Birth Multiple birth 11 37.9 
Single birth 17 62.1 
Resuscitation at birth Yes 24 77.4 
 No 7 22.6 
Antibiotic Use First 48 hours 19 61.2 
       Mean (SD) Range 
Gestational age (wks) 30.9 (1.5) 27.9 - 33.4 
Birth weight (g) 1505.3 (445.7) 703 - 2640 
Birth length (cm) 40.5 (3.6) 32.5 - 47 
Birth head circumference (cm) 28.3 (2.1) 24.0 - 34.5 
SNAPEII 7.9 (7.8) 0 - 29 
Mother age (yrs) 30.7 (8.3) 19 - 46 
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Table 2 Mixed Effects Model: Factors contributing to fecal calprotectin level 
 Estimate SE t-value p VIF 
Time interval      
Week 2 -0.585 1.798 -0.325 0.745 1.502 
Week 3 -0.123 1.798 -0.069 0.945 1.502 
Week 4 0.208 1.801 0.115 0.908 1.502 
Chronic pain/stress 0.042 0.016 2.628 0.009** 1.072 
MBM  (%) -0.189 0.276 -0.684 0.494 1.357 
HDM (%) -1.308 0.484 -2.702 0.007** 1.284 
Pre-rupture of membrane 0.670 0.210 3.198 0.001** 1.110 
Postnatal antibiotics 0.494 0.249 1.981 0.048* 1.551 
Birth Gestational age -0.043 0.080 -0.542 0.588 1.535 
Sex 0.239 0.209 1.146 0.252 1.151 
Delivery mode 0.225 0.305 0.740 0.459 1.873 
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Figure Captions:  
FIGURE 1. Fecal calprotectins in preterm infants during the first 4 weeks of life.  The boxplot 
shows the median (horizontal line) and includes the 25th (lower box border) to 75th (upper box 
border). One-way ANOVA of mean FC levels are significantly differs among 4 weeks  (F(3,190) 
= 5.609, p = 0.001).Tukey's honestly significant difference (HSD) post hoc test indicate mean FC 
level is significantly different between week1 and week2; week 2 and week4. 
 
FIGURE 2. Unweighted weekly mean pain/stressors during the first 4 postnatal weeks 
decomposed by pain/stress severity levels. 1A - Acute pain/stressors (frequency); 1B - Chronic 
pain/stressors (hours). 
 
FIGURE 3. Fecal calprotectin levels in preterm infants who had A. low (blue) and high (red) 
acute B. low (blue) and high (red) chronic pain/stress procedure scores during first four postnatal 
weeks. The dot and the error bar represent the mean value and standard error of the FCP in each 
week. 
 
FIGURE 4. Fecal calprotectin levels in preterm infants who were fed with MOM and non-MOM 
during first four postnatal weeks. The dot and the error bar represent the mean value and 
standard error of the FCP in each week. The red line represents infants who were fed with 
primarily with MOM for more than 70% of the entire feeding. The blue line represents infants 
who were fed with primarily with non-MOM for more than 70% of the entire feeding.  MOM= 
mother’s own milk; non-MOM= non-mother’s own milk.    
 
FIGURE 5. Fecal calprotectin levels in preterm infants with and without antibiotics use during 
first 4 postnatal weeks. The dot and the error bar represent the mean value and standard error of 
the FCP in each week. The red line represents infants who had antibiotics use during the first 48-
72 hours of life. The blue line represents infants without antibiotics use.  
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    A.  Acute painful/stressful procedures        
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This dissertation focuses on the interplay between pain/stress, inflammation and 
microbiota in human health. Three studies are reported herein. The study reported in chapter 2 is 
the development and testing of a tool to assess cumulative pain/stress in early life, a critical 
factor that affects the HPA axis of brain-gut-microbiota pathway. The study reported in chapter 3 
examined the effect of gut microbiome translocation on adaptive immune responses in patients 
with immunodeficiency. Chapter 4 provides the results of a study that examined the effect of 
cumulative pain/stress on gut inflammation and early programming the innate immune system. 
Cumulatively the results of the dissertation fill several gaps in our knowledge related to 
modulation of immune responses in infants and HIV patients. Overall the results demonstrate 
that the brain-gut-microbiota axis plays an important role in the modulation of both innate and 
adaptive immune responses. 
5.2 Major findings from Chapter 2 
Exposure to prolonged and cumulative stressors in early life can impair the early 
programming of neuro-immune system, particular in the vulnerable neonates who are born 
prematurely (Anand, Palmer, & Papanicolaou, 2013; Anand & Scalzo, 2000; Brummelte et al., 
2012; Fitzgerald & Beggs, 2001; Ranger & Grunau, 2014). However, most existing assessment 
tools have been developed to measure acute pain over a short period; few valid instruments are 
available to measure cumulative pain/stress among NICU infants over time.  
A nationwide online survey was conducted through the U.S. National Association of 
Neonatal Nurse's membership to assess nurses’ perceptions about severity and acuity levels 
regarding 68 painful/stressful procedures that infants commonly experience in the NICU. Based 
on the nurses’ responses, each procedure was	classified as acute, chronic, or both, and was 
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assigned a severity level from a 5-point Likert scale, with one indicating not painful/stressful and 
five indicating extremely painful/stressful. These results provide preliminary data for the 
development of an objective tool to measure cumulative pain/stress that may be generalized 
nationally with additional testing. Upon further validation, this tool will become more precise in 
measuring prolonged infant pain longitudinally. 
5.3 Major findings from Chapter 3 
Chronic inflammation has been a critical issue in HIV disease even in patients under viral 
suppressive antiretroviral therapy (ART). The underlying mechanisms of long-term humoral 
immune perturbations remain largely unknown. The study in Chapter 3 investigated the 
association between microbial translocation, and plasma anti-CD4 autoantibodies in HIV+ 
subjects under long-term viral suppressive ART treatment. 
The study found that plasma level of anti-CD4 IgGs but not anti-CD8 IgGs was increased 
in HIV+ subjects compared to healthy controls. Importantly, plasma microbial patterns differed 
between healthy controls and HIV-infected patients and between patients with low, and high 
plasma anti-CD4 IgG production. Increased plasma anti-CD4 autoantibodies production in HIV-
infected individuals was found to be associated with reduced plasma microbial diversity and a 
reduced level of Alphaproteobacteria.	These results suggest that elevated systemic microbiota 
may play a role in the induction of anti-CD4 autoantibodies in HIV infection. The study provides 
evidence which supports systemic microbiota and microbial translocation from the 
gastrointestinal tract to systemic circulation as a major driver of persistent systemic inflammation 
in HIV disease. 
5.4 Major findings from Chapter 4 
A secondary analysis of a longitudinal observational data was conducted to examine the 
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impact of cumulative pain/stress and other clinical factors in the modulation of innate 
inflammatory responses and immune-maturation in preterm infants in the neonatal intensive care 
unit (NICU). Fecal calprotectin (FCP), a non-invasive stable protein biomarker that was 
expressed primarily by neutrophils was used to measure intestinal inflammation. 
The study found that the FCP level in preterm infants during the first four postnatal 
weeks were higher than healthy term infants and adults, and presented with a wide range of 
variation both inter- and intra-individually. The mean FCP value decreased significantly from the 
first week to the second week and then increased till the fourth week. These findings reflect the 
migration of neutrophil granulocytes and macrophages to the intestinal mucosa, may suggest the 
immaturity of the immune system in preterm infants’ gut and the high permeability of gut 
mucosa.  
Chronic (prolonged) pain/stress derived from daily medical procedures in the NICU is 
positively associated with FCP levels after controlling for the confounding factors, including 
mother’s own milk, pre-rupture of membrane and antibiotics use during the first 72 hours. 
Results of this study provide, to the best of our knowledge, the first evidence for the modulation 
of chronic (prolonged) pain/stress in the early programming of the gut immune system in preterm 
infants. Further research needs to be conducted to enhance our understanding of the underlying 
mechanisms of chronic pain/stress in modulating the gut inflammatory process. 
5.5 Limitations 
The study presented in Chapter 2 intended to develop and test a tool to quantitatively 
measuring preterm infants’ cumulative pain and stress. The final score was calculated based on 
the quantity/duration and the severity of each painful/stressful procedure that infants experienced 
in the NICU. One of the limitations of this instrument development study is the failure to 
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incorporate information related to the pharmacological and nonpharmacological interventions, 
which are important factors that affect the perceived pain level of each procedure. Furthermore, 
the study results do not account fully for variability in pain/stress experience across different 
neonates’ conditions (i.e., gestational age) and different institutional contexts. These limitations 
potentially affect the sensitivity and specificity of the instrument and need to be considered in 
further development and validation of this instrument. 
The study in chapter 3 is innovative in investigating the relationship between the 
systemic bacterial microbiome and plasma anti-CD4 autoantibodies in HIV+ subjects under 
long-term viral suppressive ART treatment. The findings showed exciting results that HIV-
infected individuals with increased plasma anti-CD4 autoantibodies production presented a 
distinct microbiome pattern. However, due to the small samples size, the data failed to identify 
the bacterial species that were related to elevated autoantibodies production, which may be 
possible targets for intervention to suppress chronic auto-immune responses. In addition, the 
study did not analyze gut microbiome simultaneously with plasma microbiome. Although the 
data from the human gut microbiome project was used as a reference for the microbial 
composition comparison, the mechanisms of microbiome translocation from the gastrointestinal 
tract remains unclear.  
The small sample size is the primary limitation of the study reported in Chapter 4. It has 
been suggested that a minimum of 30 subjects is an appropriate sample size in the mixed effects 
model (Raudenbush, Bryk, Bryk, & coaut, 2002). This study failed to meet the minimum level 
for detection of significance after accounting for missing data. Due to the large number of 
missing information related to the mother’s antenatal conditions, such as medical complications 
and antibiotics use, the mother’s information was not incorporated in the analysis. Also, further 
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investigation of other inflammatory markers will help to identify the stress-inflammation 
pathway and determine the sources and mechanisms of the inflammation.  
5.6 Implication for practice, education and future research 
Results of the present study provide new knowledge about modulation of immune 
responses by the brain-gut-microbiota axis. The knowledge gained allows us to better understand 
the interplay among stress, microbiota patterns and the activation of inflammation. These 
findings also expose further unresolved questions and indicate avenues for further research 
inquiry on the roles of brain-gut-microbiome in human health. Recommendations for clinical 
practices, education and future research will be considered below:  
Cumulative pain/stress plays an important role in many aspects of infants’ health, such as 
gut immune-hemostasis and neurobehavioral development. Development of Cumulative 
Pain/Stress Scales (APSS), a customized instrument offers considerable potential to track, 
measure and manage cumulative pain/stress in NICU setting.	Awareness of cumulative 
pain/stress scores will also provide NICU nurses’ the ability to identify the infants with an 
increased risk of adverse consequences, and to offer neuroprotective interventions, such as skin-
to-skin contact, to promote more favorable developmental outcomes. 
Results from Chapters 3 and 4 suggest that the enteral bacterial composition and function 
play an important role in modulating the immune responses. Thus, the involvement of gut 
microbiome and microbial translocation in mediating gut immune responses will be a necessary 
step. Incorporating gut microbiome patterns, specifically microbial diversity, composition, and 
function will help us further understanding of the roles of pain/stress and other external stimuli in 
the modulation of FC expression in preterm infants, and more generally, the immune responses. 
Understanding the role of gut microbiome will provide knowledge to develop the individualized 
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intervention that targeting on individual gut microbiome community, in order to modulate 
immune responses. 
The study presented in Chapter 4 provides preliminary information for generating 
normative values of FCP in preterm infants. Results of the study revealed the effects of 
cumulative pain/stress, early enteral feeding, antibiotics use and pre-rupture of membranes on 
FCP levels in preterm infants during the first four postnatal weeks. The finding advanced current 
knowledge on the role of cumulative pain/stress in infants’ health outcomes. More research is 
needed that explores how the gut inflammation mediate the impacts of cumulative pain/stress, 
and other clinical factors (i.e., feeding regimen, antibiotics use) on preterm infants’ health 
outcomes, particularly neuro-behavioral development. Other inflammatory mediators, for 
example, pro-inflammatory cytokines and gut microbiome need to be analyzed simultaneously 
with FCP to map the inflammatory pathways and to identify the sources and consequence of the 
inflammation. 
5.7 Conclusion 
Emergent evidence suggested that brain-gut-microbiome axis plays an essential role in 
human health and disease. Results from studies within this dissertation advanced our knowledge 
in understanding the interplay of stress, microbiome and immune responses. 
Preterm infants are born with the immature immune system. Cumulative pain/stress 
during the neonatal period, together with other factors such as feeding practice and antibiotics 
therapy can cause immune activation and production of calprotectin, thus altering immune 
function. Understanding of postnatal modification of the preterm immune system will allow 
development of individualized interventions to minimize unfavorable immune consequences. 
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Persistent systemic immune activation has been a critical issue and driving force of CD4+ 
T-cell loss even in HIV-infected patients under suppressive antiretroviral therapy. Results from 
this study revealed that plasma microbial composition in ART-treated HIV-infected subjects was 
associated with anti-CD4 autoantibodies. This finding suggested that gut and plasma microbiome 
may be an important target to reconstitute their peripheral CD4+ T cell counts. It provides a new 
avenue to develop a specific intervention to reconstitute their peripheral CD4+ T cell counts, 
reduce the risks of complications, morbidity and mortality in HIV patients. 
To further understanding the mechanisms of the interplay of stress, microbiome and host 
immunity, a larger-scale study is needed to accommodate for additional factors, including gut 
microbial patterns (diversity and abundance), other immune factors such as cytokines profile, 
toll-like receptors and immune cells, anti-inflammatory agents such as cortisol. Future studies 
should focus on the exploration of the long-term effects of microbial dysbiosis and immune 
dysfunction, particularly in the preterm infants. Understanding the mechanism will help with the 
development of an individualized intervention to restore microbial symbiosis and immune 
function, reducing morbidity and mortality rates caused by immune dysregulation and ultimately 
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